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The field of renal cell carcinoma (RCC) has evolved rapidly over the 
last five years, with the advent of novel therapies targeting specific molecular 
pathways dysregulated in RCC. The development of these drugs was via a 
classic bench-to-bedside fashion, where an understanding of the underlying 
biology in RCC permitted relevant drug development. The foundation of these 
biological insights was the careful pathologic subtyping of RCC, supported by 
advances in familial cancer genetics. These subtypes have tremendous 
clinical and biologic relevance, further illustrated by the clinical observation 
that survival outcomes in RCC may diverge more dramatically than almost 
any other cancer. 
The work presented here is divided into two areas – the first being the 
evaluation of existing clinical models for outcome predictions in RCC, and the 
second being the evaluation of molecular models in RCC, and corresponding 
molecular insights. For the first area, we focused on the clinical models 
where epidemiologists and clinicians are actively seeking an optimal 
combination of clinico-pathologic variables for subtyping patients with RCC 
and predicting survival outcomes. Indeed, the literature is replete with a 
variety of proposed pre-operative and post-operative models. However, much 
less work has been invested in comparing these multiple models to choose 
one that is performing optimally. The work presented here compares multiple 
algorithms and nomograms to select an optimal and practical predictor in 
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localized RCC that may be recommended for use internationally for individual 
prognostication and in clinical trials of adjuvant therapy. We compare several 
clinical post-operative models including the Leibovich model, the UCLA 
Integrated Staging System (UISS), the Karakiewicz nomogram, the Kattan 
nomogram and the Sorbellini nomogram, and conclude that the best 
performing model is the Karakiewicz nomogram. This finding is of relevance 
in individual patient counseling, biomarker research and pharmaceutical trial 
design for adjuvant therapy. 
For the second area on molecular models in RCC, I derive and 
evaluate useful molecular predictors in the various subtypes of RCC in terms 
of pathology and prognosis. Thus, various hitherto undescribed subtypes of 
RCC with distinct molecular and clinical profiles may be defined here. We 
have generated novel expression predictors of prognosis in clear cell RCC as 
well as papillary RCC, while concurrently generating insights into the 
molecular mechanisms underpinning these prognostic differences. For the 
rarer chromophobe RCC, we have reported a novel expression predictor 
discriminating chromophobe RCC from its close benign counterpart, renal 
oncocytoma, which was externally validated. We also found that somatic 
pairing of chromosome 19q, an unusual cytogenetic finding, was found in 
renal oncocytoma but not in chromophobe RCC, and was associated with 
deregulated oxygen-sensing response. Overall, our findings provide not only 
a comprehensive analysis of gene expression in the various molecular 
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subtypes of RCC, but has also provided multiple insights into the potential 
pathogenesis of each RCC subtype. 
Finally, I hope that this work embodied in this thesis allows the 
scientific community investigating RCC to prepare its labours with a firm 
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OVERALL BACKGROUND 
Renal cell carcinoma (RCC) is the 7th most common cancer in males 
with an estimated 131,010 new cases diagnosed with 28,100 deaths from the 
disease in the USA in 2009(Jemal et al. 2009). In the USA, it is currently the 
10th most common cancer overall. In Singapore, it is currently the 10th most 
common cancer in males. Over the last four decades, RCC is one of the few 
cancers to see a continued rise in incidence(Chow et al. 1999). This has been 
attributed to both a true increase, based on autopsy studies of individuals 
dying of unrelated causes, as well as ascertainment bias as a result of 
increased screening(Chow et al. 1999). Approximately 70% of the patients 
with RCC presents with localized disease, which is usually curative with 
nephrectomy. However, about a third of these patients eventually develop 
metastases during the course of follow-up(Mejean et al. 2003). The overall 
prognosis for metastatic RCC is poor, and even the development of novel 
agents used in systemic therapy has yielded only modest benefits(Rini et al. 
2009). However, there is substantial heterogeneity in survival within clinical 
staging groups, and individual outcome remains difficult to predict. Risk 
factors for renal cell carcinoma include male sex, obesity, smoking, dialysis, 
hypertension and underlying germline mutations of specific tumour 




Renal cell carcinoma is usually classified into several distinct histologic 
subtypes. Based on  morphologic features first proposed in 1986(Bostwick 
and Eble 1999; Thoenes et al. 1986), RCC can be divided into clear  cell 
(conventional), papillary (chromophil), chromophobe, collecting  duct, and 
unclassified subtypes. Clear cell RCC constitutes more than 80% of all kidney 
cancers(Cheville et al. 2003), with papillary RCC, the second most common 
subtype comprising 10% to 15% of kidney  cancers (Bostwick and Eble 1999). 
Rarer histologies include chromophobe RCC (approximately 5%) and 
collecting duct carcinoma (<1%). 
 While a variety of clinical models have been used for prognosticating 
RCC(Cindolo et al. 2005; Galfano et al. 2008), the understanding of genetic 
mechanisms underlying the variability in RCC behavior is more limited. 
Research in this area has been recognized as a key priority for oncology. The 
potential for identification of prognostic subgroups of patients for adjuvant 
treatment has been reinforced recently by the establishing of multi-targeted 
kinase inhibitors as a treatment modality in clear cell RCC (Hutson et al. 
2008; Motzer et al. 2007). These findings have resulted in considerable 
excitement in the oncology community.  
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CLEAR CELL RCC  
Clear cell RCC is the most common subtype of RCC (>70%), and also 
has the poorest overall prognosis(Bostwick and Eble 1999). Morphologically, 
clear cell RCC has a characteristic gross appearance, usually golden-brown 
as a result of lipid-rich cells. The tumour usually presents as a well defined 
mass, that can be heterogenous as a result of necrosis or haemorrhage. On 
microscopic appearance, it is typically characterized by malignant epithelial 
cells with clear cytoplasm and a compact-alveolar (nested) or acinar growth 
pattern interspersed with intricate, arborizing vasculature. The most common 
underlying mutation is the VHL gene mutation, which occurs as a somatic 
mutation in up to 90% of all patients with sporadic clear cell RCC(Nickerson 
et al. 2008), where there is evidence of somatic biallelic inactivation of the 
VHL gene (Chen et al. 1995) (Iliopoulos et al. 1995). It is recognized that 
clear cell RCC is also a common manifestation of the VHL syndrome(Kaelin 
2004), where germline mutations of the VHL gene predispose to the 
development of multiple tumours, including clear cell RCC, cranial and spinal 
haemangioblastoma, phaeochromocytoma and multiple visceral cysts. Most 
recently, somatic mutations of PBRM1, a component of the SWI/SNF 
chromatin remodeling complex, have been identified in approximately 41% of 
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For papillary RCC, it is similarly true that the majority of these tumours 
show  indolent behavior and have a limited risk of progression and  mortality, 
but a distinct subset displays highly aggressive  behavior. It is the second 
most common subtype comprising 10% to 15% of kidney cancers with an 
estimated annual incidence of between 3,500 and 5,000 cases in the United 
States (Jemal et al. 2009). Delahunt and Eble have proposed that papillary 
RCC can be morphologically  classified into two subtypes (Figure 1, preceding 
page) (Delahunt and Eble 1997). Type 1 is characterized by  the presence of 
small cuboidal cells covering thin papillae,  with a single line of small uniform 
nuclei and basophilic cytoplasm.  Type 2 is characterized by the presence of 
large tumour cells  with eosinophilic cytoplasm and pseudostratification. 
Generally,  type 2 tumours have a poorer prognosis than type 1 tumours 
(Waldert et al. 2008). However, the morphologic classification remains 
controversial,  and there is limited molecular and biochemical evidence to 
support  this morphologic classification. The relatively high incidence  of mixed 
type 1 and 2 tumours poses additional difficulties for  such a method of 
classification. As a result, some studies  of papillary RCC do not stratify 
papillary RCC into type 1 and 2 tumours (Cheville et al. 2003). Despite the 
moderate incidence of PRCC, comparable to that of chronic myeloid 
leukemia, there is a disproportionately limited knowledge about the underlying 




Chromophobe RCCs account for about 4-8% of all renal tumours, with 
a more favorable prognosis relative to clear cell renal cell carcinoma, which 
comprises the majority of all RCCs (Cheville et al. 2003).  On the other hand, 
oncocytoma is the most common benign renal tumour, comprising 5-8% of 
resected renal masses. The overlapping characteristics of these entities may 
be explained by a possible common origin from the intercalated cells of the 
distal tubule (Storkel et al. 1989).  Patients with Birt-Hogg-Dubé (BHD) 
syndrome, a familial multi-tumour syndrome linked to mutation of the BHD 
gene, exhibit bilateral oncocytomas, chRCC and hybrid tumours (Khoo et al. 
2001; Nickerson et al. 2002). 
 
DIAGNOSIS 
Patients present to clinicians either in the asymptomatic setting 
(screening) or with a variety of symptoms that may be suggestive of either the 
local extension of the tumour, or the systemic spread of the cancer to distant 
sites. Local symptoms may include haematuria, loin pain or abdominal mass. 
Systemic symptoms may include fever, loss of appetite or weight, organ 
compromise or paraneoplastic symptoms. Patient evaluation for primary RCC 
involves usually radiologic imaging of the abdomen, using modalities such as 
ultrasound, computed tomographic scanning or magnetic resonance imaging. 
The use of urine cytology for histological confirmation of RCC is usually of low 
yield. The demonstration of a renal mass is followed by a clinical decision as 
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to the appropriate intervention: while renal masses may be biopsied to 
determine its nature, it is most often that clinicians will decide based on 




The treatment of renal cell carcinoma depends on the final pathologic 
and radiologic staging of the patient. Essentially, in the localized setting, a 
complete resection of the tumour is regarded as the standard of care. The 
current approach involves a nephrectomy (or removal of the kidney), with or 
without radical lymph node dissection. It should be noted that in the elderly 
and asymptomatic, or in patients with multiple comorbidities, a decision for 
surveillance may be undertaken(Chen and Uzzo 2009), to evaluate if the 
disease is indolent. In the metastatic setting, the standard of care involves the 
consideration of nephrectomy, with the first-line use of targeted therapies. 
Unusually, removal of the primary tumour has been demonstrated to confer a 
low, but definite survival benefit in patients with metastatic disease(Flanigan 
et al. 2001; Flanigan 2004). In the selection of targeted therapy for patients, 
tumour histology and risk stratification of patients are regarded as the primary 
factors of importance. The most widely used model for risk stratification 
currently is the MSKCC model(Motzer et al. 1999; Motzer et al. 2004), which 
classifies patients according to the presence of several adverse prognostic 
factors: Karnofsky performance scale of 70 or less, the presence of anaemia, 
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corrected serum calcium above the upper limit of normal, time from 
diagnosis/nephrectomy to therapy of less than one year, serum lactate 
dehydrogenase levels greater than 1.5 times the upper limit of normal. 
Patients with none of these factors are regarded as good prognosis; those 
with 1 or 2 factors considered as intermediate risk; patients with 3 or more 
factors considered as poor-risk. Currently, in patients who are categorized as 
good- or intermediate- prognosis by the Memorial Sloan-Kettering Cancer 
Centre (MSKCC) criteria, the standard of care for first-line treatment is a 
targeted therapy utilizing tyrosine kinase inhibitors, most commonly sunitinib, 
but which include agents such as sorafenib and bevacizumab in combination 
with interferon(Rini 2009). For patients with poor-prognosis MSKCC, the 
current standard of care is an mTOR inhibitor administered intravenously 
(temsirolimus) (Hudes et al. 2007). The current second-line standard of care 
following failure of first-line VEGF-targeted therapy is everolimus(Motzer et al. 
2008). Adjuvant therapy using antiangiogenic therapy is currently under active 
research with several ongoing clinical trials recruiting patients. Based on the 
success of sunitinib and sorafenib, the UK Medical Research Council (MRC) 
SORCE and the Sunitinib Treatment of Renal Adjuvant Cancer (STAR) multi-
centre Phase III trials are ongoing. Respectively, these trials are testing 
placebo versus sorafenib versus sunitinib, as well as sunitinib versus placebo 







We aim to evaluate both clinical and molecular parameters of RCC, a 
heterogenous disease, with a view to determining underlying mechanisms of 
disease and developing useful models for predicting survival outcomes. We 
aimed to evaluate how molecular profiling may improve or complement these 
survival predictions, and how these studies may provide biologic insight on 
the clinical heterogeneity observed.  
SPECIFIC AIMS (CLINICAL MODELS) 
To evaluate clinical models in predicting survival outcomes in patients with 
renal cell carcinoma; 
SPECIFIC AIMS (MOLECULAR MODELS) 
To evaluate the molecular profiles of three primary subtypes of RCC clear cell 
RCC, papillary RCC and chromophobe RCC using high-throughput gene 
expression profiling technology. This would be in the context of clinical 
outcomes, specifically survival, regional gene expression biases, high 
throughput single-nucleotide polymorphism profiling and protein expression, 
using immunohistochemistry. 
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CLINICAL MODELS IN RENAL CELL CARCINOMA 
BACKGROUND 
CLINICAL PROGNOSTIC MODELS 
From a clinical viewpoint, there are several prognostic models and 
nomograms developed to estimate survival outcomes of patients with 
localized RCC(Cindolo et al. 2005). These models are used in clinical practice 
to aid in counseling, follow-up planning and most recently, patient 
classification into groups for trials of adjuvant therapy(Haas and Uzzo 2008). 
However, there is substantial heterogeneity in survival within clinical staging 
groups, and individual outcomes remain difficult to predict. These prognostic 
models and nomograms incorporate multiple clinical and pathologic variables 
in their scoring. There are several prognostic risk groups and nomograms 
developed to estimate outcomes of patients with localized renal cell 
carcinoma (RCC), for whom there is an overall relapse risk of between 20-
30%(Cindolo et al. 2005). We present a summary table describing the key 
similarities and differences between risk grouping models and nomograms 
(Table 1, following page). It should be noted in particular that risk grouping 
models are far more widespread in clinical acceptance than nomograms, 




Table 1: Comparison of algorithms and nomograms in predicting survival outcomes 
 
  Algorithms Nomograms 
Objective and 
Approach 
To predict outcomes for the 
individual patient by classifying 
similar, but not identical, 
patients into risk groups, where 
all patients in the risk group 
have the same predicted 
outcome 
To predict outcomes for patients 
using formulae that computes 
predictions for the individualized 
patient, rather than for risk groups. 
Points on a semicontinuous scale 





Relatively fewer groups on a 
semiquantitative, or ordinal 
scale (e.g. classification into 
groups of low-, medium- and 
high- risk patients) 
 
A directly calculated quantitative 
outcome on a numerical scale (e.g. 
predicted overall survival of 69% at 
5 years for a patient) 
Clinical use Widespread e.g. International Prognostic Index in lymphoma 
 





UCLA Integrated Staging 
System, Leibovich score 
 
Karakiewicz nomogram, Kattan 
nomogram, Sorbellini nomogram 
 
 
A recent systematic review(Galfano et al. 2008) found 11 different 
mathematical models proposed for this purpose, including both models 
describing risk groups and nomograms. Unlike risk groupings (the most 
common approach), nomograms use continuous scales and thus are able to 
calculate the continuous probability of a particular outcome. This maximizes 
the predictive power of the nomogram as it eliminates the spectrum bias that 
occurs when predictors are stratified(Karakiewicz and Hutterer 2007). 
However, these nomograms have not been used within trial design simply 
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and the SSIGN scores have been validated in Western populations of 
patients with clear cell RCC (Cindolo et al. 2005; Ficarra et al. 2006; Han et 
al. 2003; Patard et al. 2004), and the SSIGN score has been validated in Asia 
(Fujii et al. 2008), the Leibovich score has not been previously externally 
validated in any population. The first direct comparison of the UISS and the 
SSIGN performed in Italy (Ficarra et al. 2009) reported that the SSIGN score 
is more accurate than the UISS for predicting cancer specific survival in 
patients with clear cell RCC, using a comparison of the respective areas 
under the ROC curve (AUC).  
With the introduction of the UISS and the Leibovich scores (Table 3, 
following page) into inclusion criteria of separate Phase III adjuvant trials, it is 
urgently required that the utility of these scores be directly compared to 
ensure uniformity of future trial designs and minimize confusion. In particular, 
the absence of external validation of the Leibovich score was noted. The UK 
MRC SORCE trial is currently recruiting patients with intermediate and high-
risk Leibovich scores for randomization between placebo and sorafenib. Both 
the ASSURE (ECOG 2805) trial (comparing placebo versus sorafenib versus 
sunitinib) and the S-TRAC trial (comparing sunitinib versus placebo) are 
selecting patients for adjuvant therapy based on UISS scores. To our 
knowledge, the SSIGN score is not used currently for selection of patients in 




Table 3 : Leibovich Algorithm to predict metastasis after nephrectomy 
Feature  Score 

























In contrast, nomograms have received far less attention as compared 
to models involving risk groups. The Kattan nomogram (Kattan et al. 2001) 
and Karakiewicz nomogram (Karakiewicz and Hutterer 2007) are two such 
nomogram-based models. The Kattan nomogram (Figure 2, following page) 
was developed in 2001 to predict 5-year disease-free survival (DFS) in 
patients undergoing radical nephrectomy for non-metastatic RCC. The 
variables used in this post-operative nomogram were symptoms, histological 
subtype, pathological tumour size and T-stage. More recently, the 
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Karakiewicz nomogram (Figure 3, following page) was developed to predict 1-
, 2-, 5-, and 10- year cancer-specific survival (CSS) of patients undergoing 
nephrectomy for RCC of all stages. The Karakiewicz nomogram was 
designed as a post-operative nomogram with the variables T, N and M 
stages, tumour size, Furhman grade, histological type, age and symptom 
classification.  
Overall, there have been more new models than comparative studies 
for selecting an optimal model. We therefore chose to perform a comparative 
effectiveness study to clarify the field by externally validating the various 
models, rather than develop another model from a relatively smaller dataset. 
The two algorithm-based models, the UISS and the Leibovich models have 
been incorporated for patient selection in large trials of adjuvant therapy in 
RCC. The UK Medical Research Council SORCE trial is currently recruiting 
patients with intermediate and high-risk Leibovich scores for randomization 
between placebo and sorafenib. Both the adjuvant sorafenib or sunitinib for 
unfavorable renal carcinoma (Eastern Cooperative Oncology Group [ECOG] 
2805) trial (comparing placebo vs sorafenib vs sunitinib) and the Sunitinib 
Treatment of Renal Adjuvant Cancer trial (comparing sunitinib vs placebo) are 
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While both the above-discussed UISS and the Leibovich models are  
risk grouping methods to predict outcomes for patients(Kattan 2008), 
nomograms differ from risk groups in several relevant ways, as described 
earlier. These models are used in clinical practice to aid in counseling, follow-
up planning and most recently, patient classification into groups for trials of 
adjuvant therapy(Borowiak et al. 2004). To illustrate the current use of risk 
grouping, the UK Medical Research Council SORCE trial is recruiting patients 
with intermediate and high-risk Leibovich scores for randomization between 
sorafenib and placebo(Eisen 2007), whereas the ASSURE and the Sunitinib 
Treatment of Renal Adjuvant Cancer (S-TRAC) trials are selecting patients 
based on modified UCLA Integrated Staging System (UISS) criteria. Although 
it is recognized that nomograms often outperform risk grouping(Di Blasio et 
al. 2003), nomograms have not been integrated into RCC clinical trials, and 
no study has comprehensively examined nomogram performance relative to 
that of risk grouping in predicting survival in RCC. Several studies evaluating 
nomogram performance have imposed multiple thresholds on the nomogram 
outcomes(Cindolo et al. 2005; Liu et al. 2009), with no disclaimer of 
exploratory analysis or expanded justification presented for the selection of 
these thresholds.  
While discretization of a continuous variable inevitably results in a loss 
of statistical information(Morgan and Elashoff 1987), this is practically difficult 
to avoid in a trial setting, where thresholds for patient recruitment are used. 
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For implementation of a trial design using nomograms, a single threshold for 
discretizing risk, so as to divide patients into two risk-groups, is usually most 
useful for establishing clear inclusion criteria and for decision making by 
clinicians and patients.  
Several post-operative clinical nomograms have been recently 
developed for RCC(Galfano et al. 2008). The Kattan nomogram was 
developed to predict 5-year freedom-from-recurrence (FFR) in patients 
undergoing radical nephrectomy for non-metastatic RCC(Kattan et al. 2001). 
The variables used in this post-operative nomogram were symptoms, 
histological subtype, tumour size and T-classification. More recently, the 
Karakiewicz nomogram was developed to predict 1-, 2-, 5-, and 10- year 
cancer-specific survival (CSS) of patients undergoing nephrectomy for RCC 
of all stages. The Karakiewicz nomogram was designed as a post-operative 
nomogram with the variables T, N and M classifications, size, Fuhrman grade, 
histologic subtype, age and symptom classification(Karakiewicz et al. 2007). 
The Sorbellini nomogram was developed to predict 5-year FFR for patients 
undergoing surgical treatment for localized clear cell RCC, using tumour size, 
T classification, Fuhrman grade, tumour necrosis, vascular invasion, and 
symptom presentation(Sorbellini et al. 2005). 
Despite the multiple RCC nomograms published in the literature, none 
are currently in widespread clinical use. Instead, ongoing clinical trials employ 
risk grouping for risk estimation and patient selection. The UK Medical 
Research Council SORCE trial is recruiting patients with intermediate and 
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high-risk Leibovich scores for randomization between sorafenib and 
placebo(Eisen 2007), whereas the ASSURE and the Sunitinib Treatment of 
Renal Adjuvant Cancer (S-TRAC) trials are selecting patients based on 
modified UCLA Integrated Staging System (UISS) criteria. In evaluating risk 
group performance, we have shown that the SORCE trial criteria (a 
discretized Leibovich model) performs better in discrimination than the 
ASSURE trial criteria (a discretized modified-UISS model). The purpose of 
the present study was to clarify which clinical model is most useful for survival 
prediction in localized RCC, so as to establish a standard for guiding trial 
design and biomarker research.  
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AIMS (CLINICAL MODELS) 
To evaluate clinical models in predicting survival outcomes in patients 
with renal cell carcinoma, and determining which clinical and pathologic 




We conducted two distinct analyses of the data, in order to account for 
differences in the selection criteria of each model. Analysis I was conducted 
for comparing the UISS and the Leibovich score, two risk models in existing 
use by pharmaceutical companies in recruiting high-risk post-nephrectomy 
patients for adjuvant trials. Analysis II was conducted for comparing 
nomograms against the best performing risk model from Analysis I. Due to 
minor differences in inclusion criteria for each model, the datasets for each 
analysis differed slightly, details of which are provided below.  
For the comparison of the UISS and the Leibovich score, we identified 
364 patients with unilateral non-metastatic clear cell RCC and who underwent 
nephrectomy at the Singapore General Hospital between 1990 and 2006 
through a comprehensive search of the Singapore General Hospital 
Pathology database and the National Cancer Centre Department of Cancer 
Informatics. ECOG (Eastern Cooperative Oncology Group) (Oken et al. 1982) 
scores exceeding 1 were excluded (n=9), as our study focused on patients 
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who were candidates for adjuvant trials. Eventually, 355 patients were 
selected for evaluation of the UISS and Leibovich scores. For the Leibovich 
model, we categorized the patients into low (0-2), intermediate (3-5) and high 
risk (≥6) groups (Leibovich et al. 2003). In terms of terminology, we refer to 
this categorization of UISS and Leibovich scores into these three risk groups 
as the UISS and the Leibovich models respectively. We refer to the 
modification of these systems into two categories (low risk versus 
intermediate and high risk groups) as either UISS or Leibovich trial criteria. 
For Analysis II, where we compared nomograms and risk models, a 
different approach to selection was adopted in view of the fact that several of 
the risk models were constructed with patient sets with different features. 413 
patients with unilateral non-metastatic RCC of all subtypes who underwent 
nephrectomy at the Singapore General Hospital between 1990 and 2006 
were identified through a database search (as contrasted to the earlier 
comparison, where only patients with clear cell histology were selected). 
Survival status and cause of death, if any, were obtained from a national 
registry. To ensure the most accurate comparisons between nomograms, we 
used an approach to select common selection criteria. Broadly, the 
Karakiewicz nomogram had the least restrictive selection criteria and similar 
to the Kattan nomogram, was applicable to all RCC subtypes. The Sorbellini 
nomogram and the Leibovich score were restricted to clear cell RCC. 
Therefore, in comparing the Karakiewicz nomogram with the Kattan 
nomogram, we excluded patients with large tumours (pT4), ECOG>1, and 
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patients with subtypes other than clear cell RCC, papillary RCC or 
chromophobe RCC (n=33), with a remaining data-set of 390 subjects. The 
ECOG limitation was imposed to ensure that this comparison would be useful 
in the appropriate patient set for trial design, and is consistent with our 
previous approach. All comparisons with the Sorbellini nomogram (n = 329) 
and the Leibovich score (n = 322) similarly were restricted to clear cell 
subtype only, and selection mirrored the more restrictive criteria of each score 
to ensure a fair comparison.  
In our studies, all specimens were reviewed by a pathologist for 
histological subtype, tumour grade, lymphovascular invasion and necrosis. 
The tumour size of pathological specimens was determined as the greatest 
dimension in centimeters and the Fuhrman grading scheme was used to 
determine the nuclear grade of tumours. Pathologic staging was determined 
in accordance with the AJCC 2002 primary tumour TNM classification,(Hudes 
et al. 2007) except when scoring the Kattan nomogram, where AJCC 1997 
stage grouping was used. The symptoms were classified as incidental, local 
(hematuria, flank pain, palpable mass), or systemic (weight loss, anorexia, 
asthenia, fever)(Bugert and Kovacs 1996). 
STATISTICAL ANALYSES 
We compared the clinico-pathologic profile of patients in our data-set 
to that of the Mayo data-set using Fisher’s exact test for categorical variables 
to assess for baseline differences. 5-year cancer specific survival (CSS), 
overall survival (OS) and disease-free survival outcomes were estimated by 
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the Kaplan-Meier method. Cox regression was also performed to evaluate the 
effect of UISS and Leibovich scores on CSS, OS and DFS separately. 
Proportional hazards assumptions were verified systematically for each score 
graphically (data not shown). To test for a difference in the predictive value of 
the UISS and Leibovich models and trial criteria for a variety of survival 
outcomes, we used the LR 2 test for nested models to assess whether the 
UISS model adds predictive value to a model including the Leibovich model, 
and vice versa, as well as whether the UISS trial criteria adds predictive value 
to a model including the Leibovich trial criteria, and vice versa. An adequacy 
index using likelihood ratio methods was used to quantify the percentage 
variation explained by a subset of the predictors (UISS or Leibovich scores 
separately) compared with the information contained in the full set of 
predictors (both UISS and Leibovich scores) by means of log-likelihood. 
Harrell’s c-index was calculated to evaluate the concordance between 
predicted and observed responses of individual subjects in terms of UISS and 
Leibovich scores separately. 
We chose three study endpoints to evaluate in common across the 
different models, these being cancer-specific survival (CSS), freedom-from-
recurrence (FFR), and overall survival (OS). CSS was defined as the interval 
between diagnosis date and cancer-related death date, or last-follow up date 
for censored patients. FFR was defined as the interval between surgery date 
and relapse date, or the date of last follow up for censored patients. OS was 
defined as the interval between diagnosis date and death date or last-follow 
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up date for censored patients. The Leibovich score was developed on 
metastasis-free survival (MFS). As there is considerable overlap between the 
definition of FFR, MFS and disease-free-survival, and hence replicated 
analyses did not show material differences between these three outcomes, 
we selected to present FFR here.  Outcomes were estimated by the Kaplan-
Meier approach, and Cox regression was used to evaluate the effects of 
covariates. Proportional hazards assumptions were verified graphically (data 
not shown). We used LR 2 of nested models to perform pairwise 
comparisons of the models involved. An adequacy index using likelihood ratio 
(LR) methods was used to quantify the percentage of the variation explained 
by a subset of the individual predictors compared with the information 
contained in the full set of predictors by means of log-likelihood(Al-Radi et al. 
2007; Harrell 2001). Harrell’s c-index was calculated to evaluate the 
concordance between predicted and observed responses of individual 
subjects separately. Calibration is useful for evaluating whether actual 
outcomes approximate predicted outcomes for each model in our dataset. For 
calibration comparisons, we evaluated each model by its defined 5-year 
survival outcome (Karakiewicz: CSS; Kattan, Sorbellini: FFR; Leibovich: 
MFS), collapsing each nomogram to approximate the risk grouping of the 
Leibovich score for greater comparability (risk thresholds 0.9 and 0.6), with 
expected outcome in each risk-group determined by the median scorer. The 
Leibovich score was calibrated by prespecified low, intermediate and high-risk 
groups(Leibovich et al. 2003). Decision curve analyses were performed to 
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determine the clinical net benefit derived by examining the theoretical 
relationship between the threshold probability of developing an event and the 
relative value of false-positive and false-negative results as described by 
Vickers et al(Vickers et al. 2009). To evaluate whether the nomogram has 
potential to outperform current standards of risk evaluation, we further tested 
several pre-specified Karakiewicz nomogram thresholds (estimated 5-year 
CSS of 0.90, 0.85 and 0.80) against the SORCE trial criteria (a discretized 
Leibovich score) using similar methodology on an exploratory basis. The 
SORCE trial criteria divided patients into low-risk (0-2) and intermediate-/high-
risk (3) individuals by Leibovich score. A separate decision analytic 
approach was also performed to determine estimated cut-off(Vickers et al. 
2009), based on a threshold benefit of 0.05, similar to considerations of 
adjuvant therapy in gastric(Paoletti et al. 2010), colorectal(Baddi and Benson 
2005), and breast cancer(Seruga et al. 2010), with a 0.5 risk reduction 
(Motzer et al. 2007). STATA 11 and R 2.11.1 were used for analysis, and all 
tests were two-sided with a significance level of 0.05.  
 
RESULTS  
The clinico-pathologic characteristics of the Singapore cohort is 
reported in Table 4 (following page). A comparison is provided against the 
Leibovich data-set; no equivalent data is available for the UCLA data-set. 
Over a median follow-up of 56 months, 78 patients had relapsed, 46 had died 
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of disease and 26 had died of causes other than cancer. The survival 
outcomes are presented as Kaplan Meier survival curves (Figure 4, following 
page).
 
Table 4 : Characteristics of patients for the comparisons between the Leibovich 
score and the UCLA Integrated Staging System (Analysis I) and between the 
nomograms and the Leibovich score (Analysis II) 
 
  Analysis I Analysis II 
Total Number of Patients 355 390 
Patients relapsing (n) 78 95 
Patients dying of RCC 46 63 
Patients dying of other causes 26 23 
Median Followup (months) 56 65 
Gender Male (%) 228 (64.2) 256 (66) 
Female (%) 127 (35.8) 134 (34) 
Age Median ± SD 57.0 ± 12.4 56.7 ± 12.4 
Race Chinese (%) 289 (81) 318 (82) 
 Non-Chinese (%) 66 (19) 72 (18) 
ECOG 0  (%) 242 (68.2) 269 (70) 
1  (%) 104 (29.3) 121 (30) 
2  (%) 6 (1.7) 0 (0) 
3  (%) 3 (0.9) 0 (0) 
Tumour Size Mean ± SD 5.9 ± 3.2 6.2 ± 3.5 
≥ 10 cm  (%) 44 (12.4) 61 (15.6) 
Pathological Stage pT1  (%) 178 (50.1) 214 (55) 
pT2  (%) 76 (21.4) 65 (17) 
pT3a  (%) 57 (16.1) 69 (18) 
pT3b/c  (%) 40 (11.3) 42 (11) 
pT4  (%) 4 (1.1) 0 (0 ) 
Fuhrman Grade 1  (%) 61 (17.2) 57 (15) 
2 (%) 186 (52.4) 206 (53) 
3  (%) 83 (23.4) 99 (25) 
4  (%) 25 (7.0) 28 (7) 
Coagulative 
necrosis 
Yes  (%) 130 (36.6) 152 (39) 
No  (%) 225 (63.4) 236  (61) 
Histology Clear cell  (%) 355 (100) 334 (86) 
Papillary  (%)   44 (11) 
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Cox regression showed that patients with a higher score (either UISS 
or Leibovich scores) have a higher chance of dying than those with a lower 
score (Table 5, following page). The concordance indices are reported in 
Table 5 as well. We show that the addition of the Leibovich model to one 
containing the UISS model significantly improves the predictive value of the 
final model, but there is no significant difference in adding the UISS model to 
the Leibovich model. A similar conclusion for the UISS and Leibovich trial 
criteria is seen for both cancer specific survival and disease-free survival, but 
there is no significant difference in terms of overall survival. The higher 
adequacy and concordance indices of the Leibovich score supports a similar 
conclusion that the Leibovich score is a superior predictor to the UISS score, 
both models used in patient recruitment for pharmaceutical trials. 
Similarly, we show that the Karakiewicz nomogram is overall the best 
performing nomogram when individually compared against the other major 
nomograms (Table 6, 7(Leibovich et al. 2003)). The Karakiewicz nomogram 
had consistently higher adequacy and concordance indices for all tested 
outcomes. Its inclusion in a full model resulted in highly statistically significant 
accuracy improvements for all outcomes when tested with LR analysis 
against the Kattan nomogram (p<0.001), the Sorbellini nomogram (p<0.001), 
with marginal improvements over the Leibovich score (p=0.04 for CSS, 
p=0.03 for DFS, with equivalent performance for OS). This supports our 
conclusion that the Karakiewicz nomogram is a superior predictor to the 
Kattan or Sorbellini nomograms. 
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Table 5 : Comparison of the various models by survival outcomes and concordance indices 
    OS CSS DFS 
  
HR  
(95% C.I.) C-index 
HR  
(95% C.I.) C-index 




















UISS model   0.64   0.65   0.66 
IR vs. LR 2.63 (1.28, 5.38)   3.94 (1.39, 11.19)   2.72 (1.50, 4.95)   
HR vs. LR 4.28 (1.92, 9.55)   6.54 (2.10, 20.34)   5.17 (2.64, 
10.12) 
  
Leibovich model   0.67   0.74   0.7 
IR vs. LR 2.05 (1.09, 3.86)   3.41 (1.30, 8.97)   2.32 (1.34, 4.02)   
HR vs. LR 5.17 (2.59, 10.32)   10.84 (4.00, 
29.41) 
  7.74 (4.32, 
13.87) 
  
UISS trial criteria   0.63   0.65   0.63 
HR/IR vs LR 3.02 (1.54, 5.93)   5.63 (2.01, 15.74)   3.27 (1.88, 5.68)   
Leibovich criteria   0.63   0.66   0.64 

























  0.64   0.7   0.66 
Kattan LR Reference   Reference   Reference   
Kattan HR 2.95 (1.84, 4.73   5.37 (2.80, 10.28)   3.54 (2.33, 5.37)   
Karakiewicz 
nomogram 
  0.71   0.75   0.71 
Karakiewicz LR     Reference   Reference   
Karakiewicz HR 5.89 (3.42, 10.14)   12.69 (5.47, 
29.45) 
  5.64 (3.59, 8.84)   
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Table 6 : Likelihood ratio testing comparisons of the Kattan and the Karakiewicz nomograms 
 Likelihood P-value Adequacy index 
 Kattan+Karakiewicz Kattan Karakiewicz Kattana Karakiewiczb Kattanc Karakiewiczd 
Kattan nomogram classification (DFS cutoff of 0.9 at 5 years) and Karakiewicz nomogram classification (CSS cutoff 
of 0.9 at 5 years) 
CSS 63.79 34.38 63.68 0.9052 <0.0001 53.9% 99.8% 
DFS 72.88 41.18 72.66 0.7340 <0.0001 56.5% 99.7% 
OS 54.87 22.83 54.36 0.4784 <0.0001 41.6% 99.1% 
Kattan nomogram and Karakiewicz nomogram as semi continuous scores 
 Kattan+Karakiewicz Kattan Karakiewicz Kattana Karakiewiczb Kattanc Karakiewiczd 
CSS 83.59 42.11 83.16 0.5113 <0.0001 50.4% 99.5% 
DFS 97.73 52.69 97.72 0.9106 <0.0001 53.9% 100.0% 
OS 65.38 31.81 64.95 0.5128 <0.0001 48.7% 99.3% 
 
a: The comparison of the model with the predictor of the Karakiewicz nomogram only with the one with predicators of both 
the Kattan nomogram and the Karakiewicz nomogram 
b: The comparison of the model with the predictor of the Kattan nomogram only with the one with predicators of both the 
Kattan nomogram and the Karakiewicz nomogram 
c: The proportion of the variation explained by the Kattan nomogram compared to that explained by both the Kattan 
nomogram and the Karakiewicz nomogram 
d: The proportion of the variation explained by the Karakiewicz nomogram compared to that explained by both the Kattan 
nomogram and the Karakiewicz nomogram 
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Table 7 : Comparison of the Karakiewicz nomogram and the Leibovich score in outcome prediction 
 Likelihood P-value Adequacy index 
 Karakiewicz+Leibovich Leibovich Karakiewicz Leibovicha Karakiewiczb Leibovichc Karakiewiczd 
Karakiewicz nomogram classification (CSS cutoff of 0.9 at 5 years) and Leibovich prognostic score 
CSS 56.94 33.54 56.90 0.8456 <0.0001 58.9% 99.9% 
DFS 72.77 53.72 69.86 0.0884 <0.0001 73.8% 96.0% 
OS 49.75 32.56 49.55 0.6535 <0.0001 65.4% 99.6% 
Karakiewicz nomogram and Leibovich scores as semi-continuous scores  
 Karakiewicz+Leibovich Leibovich Karakiewicz Leibovicha Karakiewiczb Leibovichc Karakiewiczd 
CSS 68.87 61.66 67.97 0.3426 0.0072 89.5% 98.7% 
DFS 88.40 82.31 85.73 0.1087 0.0136 93.1% 97.0% 
OS 57.71 54.65 55.10 0.1205 0.0912 94.7% 95.5% 
 
a: The comparison of the model with the predictor of the Karakiewicz nomogram only with the one with predicators of both 
the Leibovich prognostic score and the Karakiewicz nomogram 
b: The comparison of the model with the predictor of the Leibovich prognostic score only with the one with predicators 
predicators of both the Leibovich prognostic score and the Karakiewicz nomogram 
c: The proportion of the variation explained by the Leibovich prognostic score compared to that explained by both the 
Leibovich prognostic score and the Karakiewicz nomogram 
d: The proportion of the variation explained by the Karakiewicz nomogram compared to that explained by both the 
Leibovich prognostic score and the Karakiewicz nomogram
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In exploratory pairwise comparisons, we noted that several discretized 
Karakiewicz nomograms generally performed better than the ongoing SORCE 
trial criteria (a discretized Leibovich score) in terms of LR analysis, 
concordance indices and clinical net benefit in multiple survival outcomes 
(Table 6 and 7, preceding pages), particularly at the probability threshold of 
0.90. Superiority of the Karakiewicz threshold remained, but reduced as the 
threshold was reduced. Similarly, LR analysis showed consistently higher 
adequacies for the Karakiewicz nomograms at the 0.85 and 0.80 
discretizations for multiple survival outcomes, supporting superiority of the 
discretized Karakiewicz nomogram. A decision analytic method for threshold 
derivation yielded a similar approximate threshold (corresponding to predicted 
5-year CSS of 0.89, or 99 points). While for all outcomes, the 0.85 and 0.80 
discretization thresholds yielded improved net benefit relative to the SORCE 
criteria over a higher range of threshold probabilities, the SORCE criteria 
showed benefit over the 0.85 and 0.80 Karakiewicz thresholds in a more 
limited range of lower threshold probabilities. 
 The conducted likelihood ratio analyses between the UISS and the 
Leibovich score may be presented graphically for a clearer depiction of the 
relative adequacies and the analyses used to derive significance when testing 
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UISS criteria that the Leibovich score has superior outcomes relative to the 
UISS score. It is currently used by the UK MRC SORCE trial for recruiting 
intermediate and high-risk patients for randomization between placebo and 
sorafenib. Log likelihood tests showed that the addition of Karakiewicz 
nomogram classification to the model including Leibovich trial criteria 
improved the model significantly in terms of all outcomes, while addition of the 
Leibovich trial criteria to the Karakiewicz nomogram classification did not yield 
any benefits. This is true for both the semi-continuous scoring as well as the 
nomogram classification. 
To evaluate the question of whether ethnicity may have an impact on 
performance of the models, we conducted similar analyses within Chinese 
subjects (comprising approximately 82% of each cohort). The number of 
Malay and Indian subjects was too small for a meaningful validation. We 
performed comparisons of the UISS and Leibovich score, as well as 
comparisons of the Karakiewicz nomogram against the Kattan model and the 
Leibovich model, and report that the results are consistent with our findings 
above, where the Leibovich score showed superiority to the UISS model (OS: 
concordance index 0.66 vs 0.62; CSS: 0.72 vs 0.64; DFS 0.68 vs 0.63) and 
the Karakiewicz nomogram was superior to the Kattan nomogram (OS: 
concordance index 0.75 vs 0.66; CSS: 0.82 vs 0.72; FFR: 0.79 vs 0.71). A 
narrow advantage of the Karakiewicz nomogram over the Leibovich score 
based on this analysis is also reported (OS: concordance index 0.77 vs 0.76; 





LEIBOVICH AND UISS MODELS 
A number of prognostic models have been developed to improve 
survival prediction in patients with RCC. A recent systematic review found 11 
different models proposed for this purpose(Galfano et al. 2008), and the UISS 
and the Leibovich models are two such risk model based models. Over the 
last decade, several prognostic models have been developed to predict 
survival outcomes in RCC patients. Many investigators have generally 
preferred to develop new models on their own data-sets, rather than compare 
pre-existing models. There are additional models such as nomograms (the 
Kattan and the Karakiewicz nomogram), but these are less established in trial 
design. Both of the risk models, the UISS and Leibovich models, have been 
incorporated for patient selection in large trials of adjuvant therapy in RCC.  
Our results show that both the UISS and the Leibovich scores provide 
excellent estimates of various survival outcomes in our single institution 
series of patients with non-metastatic clear cell RCC, and that the Leibovich 
score is superior to the UISS score in its predictions. Ours represents the first 
such comparison of these two competing scoring systems, which is of 
particular relevance to trial design.  
A previous European study in 342 patients with non-metastatic clear 
cell RCC suggested that the SSIGN model was superior to the UISS model 
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by a comparison of an AUC of 0.830 (SSIGN) against an AUC 0.760 (UISS) 
in patients with non-metastatic RCC (Cindolo et al. 2005). In this study, no 
direct statistical testing for superiority was conducted, and it was limited to the 
prediction of cancer-specific survival. While both the SSIGN and the 
Leibovich models use the same pathologic features for scoring, the scoring 
system is distinct (SSIGN: 0 – 16, Leibovich score: 0 – 11, tiered into 3 risk 
strata). The SSIGN is designed for estimation of cancer-specific survival, but 
the Leibovich model is designed for estimation of disease-free survival. The 
urgency in direct comparison of these models has arisen from the use of the 
UISS and the Leibovich scores in the Phase III adjuvant trials. 
We have reported here that the Leibovich model is superior to the 
UISS model in estimation of all tested survival outcomes in our series, a 
finding of consequence for pharmaceutical trial design. As mentioned, the 
UISS model was developed to predict overall survival and the Leibovich 
model was developed to predict cancer-specific survival. This conclusion was 
derived using a likelihood ratio approach. While rank concordance 
methods(Harrell et al. 1996) have been used to compare the various RCC 
prognostic models, a direct comparison can be accomplished using a 
likelihood ratio-based approach, which more powerful than rank-concordance 
methods (Harrell 2001).  This approach has not been previously used, and we 
present it here together with analysis based on rank concordance methods to 
facilitate comparisons. 
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The reasons why the Leibovich model may be superior to the UISS 
model in predicting outcomes in non-metastatic patients are not immediately 
clear. However, the UISS model was developed using an automated stepwise 
modeling risk model comprising RCC tumours of all subtypes. It is recognized 
that certain pathologic variables such as tumour necrosis(Sengupta et al. 
2005) and lymph node involvement may vary in prognostic importance 
depending on tumour subtype. Thus, additional variables of prognostic 
importance may not have been eventually selected in the UISS model 
through this stepwise approach.  
 There is ongoing research in the integration of biomarkers into these 
clinico-pathologic models to enhance prediction of outcomes(Parker et al. 
2002; Parker et al. 2009). However, in the absence of definitive data 
supporting adjuvant therapy in RCC, these promising results have not entered 
routine practice in estimating survival outcomes for non-metastatic RCC.  
 
NOMOGRAMS AND RISK MODELS 
Although the Leibovich model demonstrated superiority over the UISS 
model in predicting outcomes, it is reasonable to evaluate whether other 
clinical models may yield superior outcomes. For example, multiple studies 
have documented the superior performance of nomograms when compared 
to risk groups using rank-concordance methods(Atkin and Jackson 1996; 
Belizaire et al. 2004; Brown et al. 1994; Yasui et al. 1999; Zhao et al. 2007). 
Following the establishment of the Leibovich model as the superior risk model 
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above, we proceeded to compare several nomograms against the Leibovich 
model, showing that the Karakiewicz nomogram is the most useful clinical 
predictor of survival outcomes in our data-set relative to other nomograms 
and the Leibovich model, with superior accuracy in terms of LR analyses and 
concordance indices. While the Karakiewicz nomogram was designed to test 
for CSS and the Sorbellini and Kattan nomograms for FFR, the Karakiewicz 
nomogram discriminated better in predicting CSS, FFR and OS than the other 
nomograms and the Leibovich model. Thus, in terms of individual counseling, 
the Karakiewicz nomogram is likely to be more useful that the other models.  
For nomogram comparisons, it should be noted that the Kattan 
nomogram and Karakiewicz nomogram include similar variables like T stage, 
tumour size and symptoms but they assign different weights to each variable. 
We report that the Karakiewicz nomogram is superior to the Kattan 
nomogram in estimation of all test survival outcomes in our series. We would 
like to point out that while the Karakiewicz nomogram was designed to test for 
CSS and the Kattan nomogram for RFS, the Karakiewicz nomogram 
performed better in predicting CSS, RFS and OS.  
We have used a wide array of tools for comparing the various models, 
including comparisons of discrimination (likelihood, adequacy, concordance 
indices) as well as calibration analyses. In addition to these comparisons, we 
have used decision curve analysis to show that the Karakiewicz nomogram is 
consistently superior to the other nomograms across a range of clinical 
threshold probabilities, with equivalent clinical benefit as the Leibovich score. 
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Our work provides a framework for considering the choice of model in an 
adjuvant therapy setting in RCC, best highlighted by the clinical net benefit 
analysis. It is critical to note that evaluation of clinical net benefit will evolve 
with information on benefits and toxicities of adjuvant therapy.  Practically, the 
selection of a cut-off in a clinical trial is additionally driven by trade-offs 
between event rate and accrual rate(Kattan 2010). We considered it 
interesting that the best performing cutoff for our discretization (estimated 5-
year CSS 0.90) coincided with one derived by decision analysis. Nonetheless, 
we caution here that although the Karakiewicz nomogram at all tested 
discretizations compares favorably to the SORCE trial criteria, prespecified or 
data-derived thresholds should be considered exploratory, and external 
validation of such thresholds are required for definitive conclusions on 
discretization. 
Other than improved individualized prediction, the immediate real-
world implications of our findings would be a more efficient accrual of patients 
for the ongoing adjuvant therapy RCC trials. For example, of practical real-
world interest is the finding that if the discretized Karakiewicz nomogram, 
rather than the standard trial criteria using the Leibovich score, had been 
used to select patients in our centre for the SORCE trial, 151 patients instead 
of 187 would have been recruited for 47 events in terms of cancer-specific 
survival. Other than clinical trials, the use of the Karakiewicz nomogram as a 
standard in biomarker research will allow for the development of more 
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rigorous biomarkers when the strongest available clinical model is 
incorporated into multivariable analysis. 
Overall, it is important to note that we have focused on post-operative 
nomograms rather than pre-operative nomograms, as post-operative models 
have yielded better predictions than pre-operative models(Cindolo et al. 
2005). 
As relatively unusual methods have been used to compare the models, 
we wish to discuss aspects of the model comparisons here. Although rank 
concordance methods(Harrell et al. 1996) have been used to compare the 
various RCC prognostic models, a direct comparison can be accomplished 
using a likelihood ratio-based approach, which is more powerful than rank-
concordance methods (Harrell 2001). This approach is also useful to address 
the issue of multicollinearity. In developing models with two highly correlated 
variables, as clearly occurring in our approach, multicollinearity does affect 
individual predictors, but does not reduce the predictive power or reliability of 
the full model, allowing for reliable calculations of likelihood ratios in 
comparing full versus nested models. 
THRESHOLD DETERMINATION 
There have been several studies suggesting the superior performance 
of nomograms (with multiple thresholds) compared to risk models using rank-
concordance methods (Galfano et al. 2008; Haas and Uzzo 2008; 
Karakiewicz and Hutterer 2007; Liu et al. 2009; Shariat et al. 2008). 
Nomograms are stronger predictors of survival than risk models because 
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nomograms assign points to continuous variables on a continuous scale, 
maximizing their predictive power by reducing spectrum bias. Risk models 
group patients with similar (though not identical) characteristics into risk 
groups, resulting in heterogeneity within the risk groups that reduces the 
predictive power of the risk model (spectrum bias). However, for purposes of 
a trial, categorization using a threshold is inevitable. A good analogy is that 
while a speedometer is informative, a limit is still needed whereupon 
exceeded, a policeman will issue a ticket. For example, the CALGB 90203 
trial (Eastham et al. 2003) recruited prostate cancer patients with a 
nomogram-predicted probability of 60% of remaining free from disease 
recurrence.  
The choice of an optimal cut off value for the Karakiewicz nomogram is 
selected at 0.9 at 5 years (corresponding to a nomogram score of 94) in our 
data set, which is particularly useful for stratifying patients into 2 groups. 
While a binary classification is susceptible to the usual concerns about 
categorization of semi-continuous data, it has the advantage of being simple 
and direct for trial recruitment criteria. The use of nomograms for trial 
recruitment criteria has not been done before in RCC trials, possibly because 
there are no established cut offs for practical use, and the degree of handicap 
in reducing nomograms from a continuous to a binary prediction is uncertain. 
Our study indicates that with careful selection of a threshold, a nomogram 
classification can be superior to the conventional risk models in predicting 
survival outcomes in RCC. We address the issue of loss of information by 
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categorization by providing a full analysis of Karakiewicz nomogram versus 
the other semi-continuous scores, showing that it also performs better in the 
absence of categorization. 
Hence, not only have we demonstrated superiority of the Karakiewicz 
nomogram as a continuous predictor, our results also establish that the 
Karakiewicz nomogram is able to predict survival better than the usual risk 
modelic approach even as a binary predictor, outperforming the Leibovich trial 
criteria that is currently used in clinical trials of adjuvant therapy. 
 
LIMITATIONS 
We discuss the epidemiologic issues surrounding our clinical modeling 
work here. Given that the work is essentially comprised of retrospective, 
single institution studies drawn from a hospital-based case series, this can 
raise the usual and valid concerns about selection bias and generalization of 
results to other populations. Given that the patients in our dataset were 
selected over a more recent period than either the UISS or the Leibovich 
score, stage migration may account for some of the improved outcomes in 
our series relative to the Western centres (Chow et al. 1999). However, the 
excellent calibration demonstrated generally suggests that any issue of 
generalization is likely of relatively minor concern.  
Nevertheless, it is important to note that the settings where these 
scores were derived varied as well, and with the exception of the Karakiewicz 
nomogram, were derived from data from single centres of excellence in the 
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United States. The Karakiewicz nomogram was derived from 2,530 patients in 
a range of ten academic medical centres in Europe. We agree that our 
findings need to be replicated in other populations. While population-based 
data, such as the Surveillance, Epidemiology and End-Results (SEER) 
registries, would be most appropriate for evaluation and comparison of 
nomograms, the absence of systematic collection of all evaluated variables 
precludes this possibility. 
The issue of ethnic differences and whether results based on our Asian 
population can be applicable for the Western population is a valid 
consideration. This may be partially addressed by my subsequent work in 
high throughput gene expression profiling (see Molecular Models, pg 62 
onwards) indicating that a prognostic genetic signature in clear cell RCC 
yielded excellent and similar predictions in both Japanese as well as 
American populations, suggesting that clinical models derived in the West are 
generally applicable to Asian populations. This is supported by the 
observation of excellent calibration of the Western models in our Asian 
dataset. It should be noted that our analyses of the predictions within the 
Chinese ethnic group alone (comprising approximately 80%) of the dataset 
demonstrated results similar to that derived from analyzing the full dataset. A 
future expanded number of members of the other ethnic groups will permit 
analysis of each racial group, to evaluate whether these models perform in a 
similar fashion in each racial group. It is not possible to perform similar 
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analyses in the current dataset due to the relatively small numbers of Malay 
and Indian patients.  
We describe the limitations of our comparative effectiveness study 
here. The nature of our study as a retrospective, single institution study raises 
the usual concern about generalization of results to other populations. There 
are significant baseline differences between our data-set and the Mayo and 
UCLA data-sets. It is unclear if these differences may have asymmetrically 
affected predictor generalizability and resulting performance, but individually 
assessed, both predictors performed well in our data-set. Generally our data-
set has the highest proportion of better-risk patients. In particular, the UISS 
data-set had a remarkably high proportion of high-risk patients (32%) even 
after having excluded patients with regional lymph node metastasis. The 
Mayo dataset of 1,671 patients included 66 patients with lymph node-positive 
disease; this group was excluded in our data-set to allow for direct 
comparison. Multiple explanations are possible for these baseline differences. 
Selection bias may account in part for this : the Mayo Clinic and UCLA are 
major US referral centers, which would be expected to care for a higher 
proportion of patients with advanced disease. Given that the patients in our 
data-set being selected over the most recent period, stage-migration may 
account in part for this difference (Chow et al. 1999). However, we do note 
that the SSIGN, which shares variables with the Leibovich score albeit with a 
different weighting method, has been shown to predict outcomes better than 
the UISS score in a European population.  We did not study nomogram-
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based models, since such models are not currently integrated into trial 
designs, although they do provide useful predictions for individual patients. 
VALIDITY 
The validity of studies is usually distinguished in two components – the 
inferences as they pertain to the members of the source population (internal 
validity) and people outside the source population (external validity). Our 
studies provide an overview of the critical nature of validity, with a wide range 
of techniques being applied to multiple different data-sets and tissue samples 
from a broad range of centres (Larkin et al. 2005; Quackenbush 2006b). In 
terms of validity, the Singapore dataset represents an external test set to 
evaluate the value of the multiple risk models and nomograms that have been 
generated to predict a range of outcomes.  
It should be noted that the use of adequacy indices may be misleading 
in the situation when both scores are poor predictors of survival; its use would 
lead to the potential conclusion that one model is not poorly performing 
relative to the model to both scores. However, this may not apply in our 
dataset, as each model individually has been demonstrated to yield excellent 
predictions of outcomes. 
COLINEARITY 
Given that we are comparing scores that have a degree of correlation, 
colinearity is a potential issue. Hence, a full model that incorporates both 
scores (as we do here) will definitely result in colinearity when estimating the 
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standard errors of individual beta weights. However, calculation of deviance 
(which likelihood ratio testing is based on) is less affected by colinearity, and 
hence permits us to compare full relative to nested models. It should be noted 
that the error of individual beta weights of individual prognostic scores in the 
full models will be high, but that we are not utilizing the coefficients. 
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MOLECULAR MODELS IN RENAL CELL CARCINOMA 
BACKGROUND 
We have described extensively the use of clinical modeling to estimate 
outcomes for RCC in our initial analysis. These methods, while useful, may 
benefit from additional evaluation of additional biological variables, and the 
same studies have provide additional biological insights. These inevitable 
limitations result in heterogeneity within risk groups, as well as the provision 
of probabilistic estimates for individuals by nomograms. Even while accurate, 
a probabilistic estimate is not completely satisfactory to clinicians and 
patients, since each individual has a specific individual outcome. Hence, 
additional biomarkers are of high interest in improving these estimates. These 
biomarkers may include genetic, epigenetic and molecular variables of 
interest. Recent advances in materials science, bioengineering and 
information technology have permitted the development of high throughput 
methods for determination of these profiles, and we focus here on the use of 
high throughput expression profiling in selecting candidate signatures and 
biomarkers for RCC. Generally, the use of these signatures and markers are 
important for determining cancer classes, using unsupervised methods such 
as class discovery, and correlating these outcomes with clinically relevant 
endpoints such as survival, relapse, genetic alterations as well as drug 
resistance.  
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HIGH THROUGHPUT EXPRESSION PROFILING 
We used high throughput methods, primarily gene expression profiling, 
a promising adjunct for cancer diagnosis and prognosis(Tan et al. 2004b), to 
identify prognostic predictors and genetic programs in tumour tissue 
(Quackenbush 2006b). These techniques, usually known as microarrays, 
allow for the concurrent collection of expression data of multiple transcripts 
from a single sample. These techniques allow for the measurement of 
expression data in a wide range of biological processes. With the widespread 
use of this technique in recent years, the explosion of data has resulted in the 
creation of large data repositories for archival and open access of this data, 
such as the Gene Expression Omnibus (GEO)(Sayers et al. 2010). 
Microarray experiments are associated with their own challenges, and 
these primarily centre on variation (Abdullah-Sayani et al. 2006). Data 
variation may occur as a result of technical (extraction, labelling, 
hybridization), measurement (fluorescent signal) or biological variation. 
Biological replication is the most important, but is not always possible due to 
the high costs of microarrays. Broadly, the general techniques of preparation 
for microarray analysis involve extraction of RNA (total or mRNA), purification, 
reverse transcription, labeling and hybridization. There are two major types of 
expression microarray platforms in use : oligonucleotide based and 
complementary DNA (cDNA)-based.  
The oligonucleotide array class consists of usually smaller probes, 
ranging from 25 to 80 bp in length. These may be presynthesized and spotted 
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directly onto the substrate, or synthesized directly on the substrate. This 
platform is most commonly used in the commercial Affymetrix chips, which 
depend on the spot intensity measures of oligonucleotide probes hybridized 
to the array chip. Following hybridization, the array is scanned, producing an 
image, and the relative fluorescence of each spot is ascertained. Pixel 
intensity is measured using software, and the intensity of each spot is 
normalized, allowing for comparison within and between arrays.  
cDNA arrays comprise PCR products spotted onto the array, enabling 
clone banks and DNA from limited templates to be spotted. The size of a PCR 
amplified fragment is in the order of 400 – 1000 bp. The spotted microarray is 
hybridised with probes derived from the mRNA of the biological samples 
being assessed. In the technique known as dye swapping, in which multiple 
extracts are hybridised to arrays, the mRNA is typically reverse transcribed 
into cDNA and labelled with a spectrally distinguishable red (Cy5) or green 
(Cy3) fluorescent dye. Samples are then hybridized on the microarray, 
allowing labelled cDNA strands complementary to sequences on the 
microarray to bind. Generally two dyes are used; if only one dye is used there 
is little measure of the amount of DNA targeted to any particular spot. 
However, the relative fluorescence of two dyes to each other can be 
measured, with the sample containing higher levels of transcript producing a 
greater signal.  
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After transformation of the raw data into a gene expression matrix, 
data is analysed using various packages of R and Bioconductor (Gentleman 
et al. 2004). These software packages permit the analysis of microarray 
experiments using a variety of tools for high dimensional data(Quackenbush 
2006a). 
RCC EXPRESSION PROFILING 
Studies have demonstrated that the various subtypes of RCC are 
readily distinguishable with gene expression profiling (Higgins et al. 2003; 
Takahashi et al. 2003; Yamazaki et al. 2003; Young et al. 2001). These 
results support the intuitive hypothesis that each subtype has its own 
individual biological features, clinical behavior, and, by extension, unique 
sensitivity to therapy. Although the discriminatory ability of gene expression 
profiling makes it potentially an excellent diagnostic tool, from a practical 
perspective the technology is currently not readily accessible to many 
pathologists in clinical practice. In RCC pathology, microarrays have already 
been instrumental in discovering new immunohistochemical markers for 
distinguishing the different subtypes. For example, Yamazaki et al. (Yamazaki 
et al. 2003) profiled several histologic subtypes of RCC and identified c-kit as 
being up-regulated in chromophobe RCC, and our group identified the 
following potential markers for the different histologic subtypes: glutathione S-
transferase α for clear cell RCC, α-methylacyl racemase for papillary RCC, 
carbonic anhydrase II for chromophobe RCC, and K19 for transitional cell 
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carcinoma (Takahashi et al. 2003). These studies represent a direct effort to 
enhance the practice of pathology through the use of microarray technology.  
Gene expression profiling is not limited to tumour tissue. Interestingly, 
Twine et al. (Twine et al. 2003) profiled peripheral blood mononuclear cells 
(PBMCs), instead of tumour tissue, from RCC patients and healthy volunteers 
and demonstrated that these expression profiles could distinguish the PBMCs 
of RCC patients from those of healthy volunteers. Although the biological 
significance of the identified discriminatory genes is uncertain, these 
preliminary findings are of considerable interest, because the authors indicate 
that their ongoing studies suggest that expression profiling of PBMCs can 
distinguish RCC patients from patients with other types of solid tumours. It is 
possible that additional work may establish the presence of disease-specific 
gene sets in PBMCs.  
Refining prognostic systems to more accurately predict patient 
outcomes and thereby guide more effective treatment decisions is an ongoing 
process. To date, key prognostic factors identified include TNM staging, 
tumour grade, functional status, and various biochemical assessments. 
Integrated prognostic systems have been developed by several groups 
combining clinical and pathological data to better stratify patients and improve 
prognostic power(Gettman et al. 2001; Motzer et al. 1999; Zisman et al. 
2002). Further integration of molecular markers defined by expression and 
proteomic profiling into these prognostic systems is likely to further increase 
prediction accuracy.  
 67
Our group initially reported a pilot study in which 29 specimens of clear 
cell RCC with patient-matched normal tissue were profiled with cDNA 
microarrays(Takahashi et al. 2001). In this study, unsupervised clustering 
demonstrated two subsets of tumours, with clear segregation by cause-
specific survival at 5 years. Approximately 40 genes were identified that 
discriminated between these two groups. These results suggest that there are 
two distinct groups of clear cell RCC that vary in aggressiveness. A major 
limitation of this study was the relatively small number of cases, resulting in 
the inability to externally validate the results. However, the prediction 
accuracy of 5-year survival by using microarrays exceeded that of staging, 
and accurate cross-validated predictions were obtained for patients with 
clinically indolent metastatic RCCs and clinically aggressive localized RCCs, 
which suggested that the prognostic signature was not confounded by 
metastasis. In view of the relatively small numbers of this study, we believe 
that this study should be considered preliminary, and we have sought to 
expand this study here. In particular, there is a goal of identifying high-risk 
patients with localized RCC for early systemic therapy. It is plausible that 
expression profiling will actually result in individually tailored therapeutic 
regimens in the near future. 
 
MICROARRAY PLATFORM 
The Affymetrix GeneChip platform which is used primarily here is an 
high-density oligonucleotide expression array platform. A unique gene is 
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represented by multiple such probe sets on the Affymetrix chip, with probe 
pairs comprising perfect match (PM) and mismatch (MM) probes. The PM 
probes are designed to specifically complement a 25 bp sequence in the 
target gene; the MM probes are identical to the PM probes save for a single 
base pair change in the centre position. Mismatches are supposed to 
represent non-specific hybridization. As is evident, to analyze GeneChip data, 
the probe-level preprocessing needs to be considered carefully. The four 
steps include background correction (subtraction of nonspecific background), 
normalization (reduction of non-biological signal and equalization of 
intensities across chips), PM correction (subtraction of non-specific 
hybridization) and summarization. Multiple methods exist for summarization, 
including the Affymetrix Microarray Suite (MAS 5.0) (Hubbell et al. 2002). 
Several approaches have been proposed to improve this conventional 
method, including  Model Based Expression Index (MBEI) (Li and Wong 
2001) and the Robust Multi-array Average (RMA) (Irizarry et al. 2003). 
Although RMA is used most commonly in this thesis, there are other methods 
developed such as Factor Analysis for Robust Microarray Summarization 
(FARMS) (Hochreiter et al. 2006). Each method takes a different approach 
towards summarization, but the goals are similar – to generate improved 
methods of gene expression evaluation while accounting mathematically for 
non-biological flaws and bias in data acquisition. 
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SIGNIFICANCE ANALYSIS OF MICROARRAYS 
 Advanced statistical methods are commonly used in this thesis. The 
method best known as SAM, or Significance Analysis of Microarrays (Tusher 
et al. 2001), was developed at Stanford for the identification of genes with 
statistically significant changes in expression, by evaluating a set of gene-
specific t tests. It is crucial to note that while cluster, or unsupervised analysis 
may identify specific classes of gene expression, identification of 
corresponding discriminating genes may be challenged by the large number 
of transcripts evaluated, resulting in a distinct false-discovery rate (FDR). 
SAM estimates FDR by first assigning each gene a score based on its 
change in gene expression relative to the standard deviation of repeated 
measurements for that gene. The FDR is estimated by analyzing 
permutations of the measurements, and the threshold for this can be adjusted 
to calculate varying FDRs for each set. This has a distinct advantage over the 
Bonferroni method, which assumes independence of the different tests, which 
is clearly an invalid assumption resulting in an overly conservative estimate. 
Other methods outside those discussed here include the step-down 
correction method, which permits dependent tests (Westfall et al. 2002). For 
this thesis, SAM was selected for supervised analysis primarily because of 
availability and ease; alternatives such as LIMMA(Smyth 2004) (Linear 
Models for Microarray Data) are certainly possible alternatives. LIMMA is also 
implemented in R, and is used to create and test linear models for microarray 
data. A moderated t-statistic is used to evaluate the average difference in log 
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expression levels for each gene; the t-statistic is generated by the average 
log ratio divided by a derived standard error. Several multiple comparison 
procedures may be used to control for the resulting FDR. 
 
SPECIFIC AIMS (MOLECULAR MODELS) 
To evaluate the molecular profiles of three primary subtypes of RCC – 
clear cell RCC, papillary RCC and chromophobe RCC in an unbiased fashion 
using high-throughput gene expression profiling technology to obtain 
validated clinical and mechanistic insights into diagnosis, prognosis and 
pathogenesis. The techniques used here to supplement the high throughput 
expression profiling include regional gene expression bias determination, high 
throughput single-nucleotide polymorphism profiling and protein expression, 
using immunohistochemistry. This would be in the context of correlating a 
molecular phenotype with clinical outcomes. These outcomes include 
histological discrimination / recognition, relapse and most importantly survival 





CLEAR CELL RENAL CELL CARCINOMA 
Considering the pathological and clinical issues for clear cell RCC discussed 
in Overall Background and Background (Molecular Models), our goal was to 
use gene expression profiling as a promising adjunct for cancer diagnosis and 
prognosis to identify prognostic predictors and gene expression programs 
during both primary and relapsed stages of RCC.  
METHODS 
SUBJECTS AND STUDY DESIGN 
A total of 92 primary tumour and 25 metastatic clear cell RCC tissue 
specimens from independent patients operated on in 8 centers (6 in USA, 2 in 
Japan) between 1989 and 2002 were obtained.  Japanese centres were 
University of Tokushima and University of Kitasato. US Centres included 
University of California Los Angeles,  Spectrum Health Grand Rapids, Detroit 
Wayne State University, Johns Hopkins University, University of Chicago, and 
Baylor College. Primary tumour tissue samples were acquired from patients 
diagnosed with sporadic clear cell RCC with at least two years’ follow-up 
following nephrectomy as available. Metastatic tumour tissue samples were 
acquired from patients with a history of localized clear cell RCC, who had 
relapsed with metastases after primary nephrectomy as available. These 
samples represented contributions from institutional tissue banks to the Van 
Andel Research Institute. 12 non-neoplastic kidney samples from unrelated 
patients were also obtained as controls for regional expression bias analysis; 
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these are the same 12 controls for regional expression bias used for the other 
microarray studies in other subtypes in this thesis. 
Written informed consent for analysis of clinical samples was obtained 
from all patients, and all IRB boards of participating institutions approved the 
study. Tumour tissue was flash frozen in liquid nitrogen immediately after 
nephrectomy and stored at –80°C. Portions of the tumours were fixed in 
buffered formalin. Each sample was confirmed by pathologic analysis and 
anonymized prior to the study. A portion of the tumour sample was frozen in 
liquid nitrogen immediately after surgery and stored at –80˚C. Total RNA was 
isolated from the frozen tissues using Trizol reagent (Invitrogen, Carlsbad, 
CA). This was subsequently purified with a RNeasy kit (Qiagen, CA), and 
quality was assessed on denaturing gel electrophoresis. Representative 
tissue sections of RCC were cut and stained with hematoxylin-eosin for 
confirmation of histological diagnosis and confirmation of tumour tissue 
content (>70%). All samples were examined by a central expert 
uropathologist. Clinicopathologic information was derived by review of 
pathologic, radiologic, and case notes by individual clinicians. Tumours with 
sarcomatoid change were classified as grade 4 tumours. Tumour size was 
defined as the maximum tumour dimension on direct pathological 
measurement. Patient follow-up status was assessed by directly contacting 
patients where possible, or at routine clinical follow-up. 
An a priori external validation approach was used (Figure 4), where samples 
from Japan were designated as the training set (n=33) and those from the 
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USA as the test set (n=59). The predictor was derived by 2-means clustering 
followed by application of nearest shrunken centroids(Tibshirani et al. 2002) 
for optimal derivation. The choice of a 2-means clustering approach was 
determined by previous work reporting there to be two molecular classes for 
clear cell RCC (Takahashi et al. 2001). For supervised analysis and 
hypothesis generation, the 92 oligonucleotide profiles were divided into 2 
predicted classes based on the prognostic gene predictor. 2260 
discriminating transcripts, corresponding to a delta of 3.0 with a FDR of 
approximately 0.001%, was selected for pathway analysis. In order to test this 
predictor across array platforms, we employed the following strategy to 
assess coexpression across different microarray platforms and hybridization 
designs, since differing data structures preclude direct application of the 
oligonucleotide predictor to two-channel spotted cDNA data. Accordingly, we 
tested our predictor in the complete microarray dataset of a Stanford dataset 
of Swedish patients with clear cell RCC (GEO GSE3538) (n=177) (hereafter 
referred to as the Stanford dataset). (Zhao et al. 2006) We identified well-
measured (<50% missing data) expression values of matching cDNA clones. 
K-nearest neighbour imputation (10 neighbours, largest block of 1,500 
transcripts) was used to impute remaining missing values and hierarchical 
clustering was applied on the data. Imputation was required to avoid omission 
of samples. Of genes overlapping the oligonucleotide predictor and the 










































































































micrograms of total RNA was used to prepare antisense biotinylated RNA. A 
subset of cases were spiked with external poly(A) RNA controls. Synthesis of 
single-stranged and double-stranded cDNA was done with the use of T7-
oligo(dT) primer (Affymetrix). In vitro transcription was done using Enzo 
Bioarray Transcript Labeling kit (Enzo, Farmingdale, NY). The biotinylated 
cRNA was subsequently fragmented and 10 micrograms were hybridized to 
each array at 45°C ovr 16 hours. We used the HGU133 Plus 2.0 GeneChip, 
containing 54,675 probe sets, representing approximately 47,000 transcripts 
and variants. Scanning was done in a GeneChip 3000 scanner. Quality 
indices reviewed for all samples included mean percentage present, mean 
background, mean scaling factor and a mean GADPH 3’/5’ ratio. All clinical 
and microarray data for published data has been uploaded to the Gene 
Expression Omnibus.  
STATISTICAL ANALYSES 
Statistical analyses were performed with R, utilizing packages from the 
Bioconductor project(Gautier et al. 2004; Gentleman et al. 2004) Packages 
used include affy (Gautier et al. 2004), survival, and impute. The default 
significance threshold was 0.05. For pre-processing of the Affymetrix data, 
the robust multichip average (RMA) algorithm was the default method used to 
perform background adjustment, quantile normalization and summarization.  
All survival analyses were performed by fitting the data to a Cox proportional-
hazards model, and the end point of interest was disease-specific mortality. 
Overall survival time in all patient groups was defined as the time from initial 
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nephrectomy to the date of death or the last known date of contact with 
provider. Nagelkerke’s R2 values have been used to report goodness-of-fit, 
where a value of 1 represents a perfect fit. Where appropriate, bivariate 
survival analysis was performed, the utility of the predictor being assessed 
after adjusting for clinicopathologic parameters singly; this approach was 
selected rather than multivariate analysis based on available event numbers. 
Case deletion was used for missing data. Adjusted variables included age, 
gender, tumour stage, metastatic status, tumour size, tumour grade, Eastern 
Clinical Oncology Group (ECOG) performance status and UCLA Integrated 
Staging System (UISS) status. Significance levels in all cases were calculated 
with the likelihood ratio test. 
Regional expression biases are genetic intervals where gene 
expression is coordinately changed, corresponding well with cytogenetic 
aberrations detected by comparative genomic hybridization. We inferred 
cytogenetic profiles for the tumours through the use of a refinement of the 
comparative genomic microarray analysis (CGMA) risk model, which predicts 
chromosomal alterations based on regional changes in expression. Briefly, for 
each measured gene, the gene expression value was normalized such that 
the average gene expression value in the nondiseased samples was 
subtracted from the tumour-derived gene expression value. Relative 
expression profiles (R) were generated from the single-channel tumour 
expression profiles (T) and the mean expression values of the 12 single-
channel kidney cortical expression profiles (N), such that R = log2(T) – log2(N). 
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The improved resolution-comparative genomic microarray analysis (IR-
CGMA) risk model that we had previously reported was applied to achieve 
this.  Chromosomal abnormalities was predicted as implemented in the reb 
package (Furge et al. 2005).  
 
PATHWAY ANALYSIS 
For pathway analysis, the Ingenuity Pathways database version 3.0 
(Ingenuity Systems, Mountain View, CA) was used. A list of transcripts was 
generated using significance analysis of microarrays (SAM) based on a 2-
class unpaired analysis with 1000 permutations.  
 
IMMUNOHISTOCHEMISTRY 
Immunohistochemistry (IHC) was performed using CD31. CD31 is a 
transmembrane protein expressed in vascular endothelium, and CD31 
immunostaining is commonly used for assessment of microvessel density 
(MVD). 45 formalin-fixed paraffin-embedded tissue specimens from patients 
operated between 1993 and 2002 were obtained from 3 centers. Automated 
immunostaining was performed with the murine anti-human monoclonal 
antibody, clone JC/70A (M0823) (30 min incubation at room temperature). 1 
slide was stained per specimen. We employed a modified strategy to 
maximize correlation between mRNA expression in bulk tissue and CD31 
immunostaining. 9 fields (each 0.2596 mm2 in size) at 200X magnification 
were captured (Spot Insight Camera, Nikon Eclipse E600) in a 3 x 3 
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arrangement with the widest possible distribution across each slide, avoiding 
areas of necrosis. MVD was calculated as the mean count over the 9 images. 
Interactive image analysis was performed using Cytometrix, an in-house 
program developed for quantitative analysis of histologic images. 
Immunostaining, image capture and analysis were performed independently 
by blinded individuals. A countable microvessel was defined as a stained 
endothelial cell cluster with or without a lumen distinct from other cell clusters. 
Contiguous or anastomosing structures were considered as one microvessel. 
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RESULTS AND DISCUSSION 
Baseline characteristics of the patients of the Japanese and the US 
cohort are presented in Table 8 (following page) 
 
Prognostic predictors were identified, externally validated and 
demonstrated to be independent of standard clinicopathologic 
parameters. We defined a prognostic oligonucleotide predictor (Table 9, pg 
81) using unsupervised (2-means clustering) methods in Japanese patients 
(R2 = 0.276, p=0.003) (Figure 10, pg 83), which successfully predicted 
survival in a separate test set comprising tumours from patients from 6 US 
centers (R2 = 0.236, p=0.0001) (Figure 10, pg 83). Respective expression 
data is shown (Figure 11A-B, pg 85). Bivariate analysis in the test set 
demonstrated that the predictor remained significant after adjusting for 
standard clinicopathologic parameters, including the UCLA Integrated Staging 
System (UISS), an aggregate variable of stage, grade and functional status 
(Table 10, page 82). 
 
The prognostic predictor demonstrated utility in patients with 
metastasis at relapse. We demonstrated utility for the predictor from the 
primary tumour data set in metastatic clear cell RCC samples resected from a 
variety of distant sites after relapse (R2 = 0.228, p=0.03) (Figure 10, pg 83).  
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Table 8 : Individual patient demographic data for the clear cell RCC dataset 
Country   Japan USA 
Number of samples   33 59 
Age Range 39 – 80 34 - 82 
  Median 62 62 
Gender – n (%) Male 24 (73) 36 (61) 
  Female 9 (27) 23 (39) 
TNM stage – n (%) 1 15 (45) 20 (34) 
  2 4 (12) 5 (8) 
  3 7 (21) 19 (32) 
  4 7 (21) 15 (25) 
Tumour T stage – n (%) 1 17 (52) 22 (37) 
  2 8 (24) 8 (14) 
  3 8 (24) 28 (4) 
  4 0 (0) 1 (2) 
Tumour M stage – n (%) 0 26 (79) 44 (75) 
  1 7 (21) 15 (25) 
Tumour Grade – n (%) 1 13 (39) 2 (3) 
  2 13 (39) 24 (41) 
  3 7 (21) 24 (41) 
  4 0 (0) 9 (15) 
Tumour size – cm (%) Range  2.5 – 17 1.4 - 19.5 
  Median 5.2 6 
  Unknown 2 3 
ECOG PS – n (%) 0 20 (71) 28 (47) 
  1 7 (25) 28 (47) 
  2 1 (4) 3 (5) 
  Unknown 5 0 
UISS staging – n (%) 1 11 (39) 9 (15) 
  2 11 (39) 26 (44) 
  3 2 (7) 7 (12) 
  4 4 (14) 16 (27) 
  5 0 (0) 1 (2) 
  Unknown 5 0 
Post-nephrectomy 
treatment  – n (%) 
Palliative 
immunotherapy 5 (15) 12 (20) 
Immunotherapy response  Complete response  0  0  
  Partial response 0  2  
  Stable disease 1  1  
  Progressive disease 4  9 
Patient status – n (%) 
Deaths (cancer 
related) 9 (27) 22 (37) 
 Deaths (other causes) 4 (12) 2 (3) 
 Alive with disease 3 (9) 7 (12) 
 No evidence disease 17 (51) 28 (47) 
Follow-up duration(yr) Mean 5.5  2.9 
 Range 0.25 – 11.7 0.05 – 9.3 
ECOG PS: Eastern Cooperative Oncology Group Performance Status  
The total percentage count for each category may not total to 100 due to rounding.  
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Table 9 : Prognostic predictor of transcripts in clear cell RCC 
Affymetrix Probe 





238178_at EST Transcribed locus 0.4703 -0.4997
238066_at RBP7 retinol binding protein 7, cellular 0.2399 -0.2549
228434_at BTNL9 butyrophilin-like 9 0.2397 -0.2547
217177_s_at EST CDNA FLJ13658 fis, clone PLACE1011567 0.1511 -0.1606
204368_at SLCO2A1 
solute carrier organic anion transporter family, member 
2A1 0.147 -0.1561
227874_at EST MRNA; cDNA DKFZp586N0121 0.131 -0.1392
219436_s_at EMCN endomucin 0.1264 -0.1343
205478_at PPP1R1A protein phosphatase 1, regulatory (inhibitor) subunit 1A -0.124 0.1317
219304_s_at PDGFD platelet derived growth factor D 0.1238 -0.1316
228575_at FNDC6 fibronectin type III domain containing 6 -0.1133 0.1204
230250_at PTPRB Protein tyrosine phosphatase, receptor type, B 0.1086 -0.1153
204273_at EDNRB endothelin receptor type B 0.1035 -0.1099
238649_at PITPNC1 phosphatidylinositol transfer protein, cytoplasmic 1 0.0899 -0.0956
205651_x_at RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 0.0896 -0.0952
204271_s_at EDNRB endothelin receptor type B 0.0894 -0.095
205357_s_at AGTR1 angiotensin II receptor, type 1 0.0858 -0.0911
202242_at TSPAN7 tetraspanin 7 0.0796 -0.0846
209047_at AQP1 aquaporin 1 (Colton blood group) 0.0724 -0.0769
201150_s_at TIMP3 TIMP metallopeptidase inhibitor 3  0.0718 -0.0763
203934_at KDR kinase insert domain receptor  0.06 -0.0638
221031_s_at APOLD1 apolipoprotein L domain containing 1 0.0507 -0.0538
219315_s_at C16orf30 chromosome 16 open reading frame 30 0.0502 -0.0534
230645_at FRMD3 FERM domain containing 3 0.0449 -0.0477
224215_s_at DLL1 delta-like 1 (Drosophila) 0.0428 -0.0455
209147_s_at PPAP2A phosphatidic acid phosphatase type 2A 0.0389 -0.0413
208096_s_at COL21A1 collagen, type XXI, alpha 1 0.036 -0.0383
205846_at PTPRB protein tyrosine phosphatase, receptor type, B 0.0341 -0.0363
218723_s_at RGC32 response gene to complement 32 0.0311 -0.0331
207542_s_at AQP1 aquaporin 1 (Colton blood group) 0.0191 -0.0203
206701_x_at EDNRB endothelin receptor type B 0.0187 -0.0199
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238169_at EST Transcribed locus 0.0141 -0.015
1560359_at PELO Pelota homolog (Drosophila) 0.0072 -0.0077
1555725_a_at RGS5 regulator of G-protein signalling 5 0.0065 -0.0069
222717_at SDPR serum deprivation response  0.0053 -0.0056
205150_s_at KIAA0644 KIAA0644 gene product 0.0045 -0.0048
212230_at PPAP2B phosphatidic acid phosphatase type 2B 0.0035 -0.0037
227372_s_at BAIAP2L1 BAI1-associated protein 2-like 1 -9.00E-04 9.00E-04
 
 










ratio of predictor 
95% 
confidence 
intervals p-value  
Unadjusted 6.25 2.10-18.6
Age 6.44 2.15-19.3 0.0001
Sex 6.20 2.06-18.6 0.0002
Stage 3.28 1.01-10.6 0.03




Size (>4 cm)* 4.70 1.50-14.8 0.005
ECOG PS 6.48 2.15-19.5 0.0001
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Matching genes in the prognostic predictor demonstrated utility 
in an external dataset. Although only 2 of 37 transcripts in our 
oligonucleotide predictor were a priori determined as being of sufficient quality 
in the Stanford spotted cDNA dataset, being PPAP2B (T71976) and EDNRB 
(H28710) (Figure 11, following page), hierarchical clustering of the sample 
data with these 2 genes generated 2 distinct prognostic clusters (R2 = 0.05, p 
= 0.005) (Figures 11, following page). Nonetheless, it is clear from the much 
reduced R2 that using these 2 genes only would certainly result in a poorer 
prediction relative to a potential full transcript predictor. 
Prognostic chromosomal aberrations were inferred from the 
expression profiles We inferred chromosomal aberrations associated with 
these distinct molecular subtypes of clear cell RCC with CGMA (Figure 11E, 
following page). This technique identified distinct regional expression biases 
corresponding to common cytogenetic abnormalities in clear cell RCC(Kovacs 
and Brusa 1988), such as deletions of chromosomes 3p, 6q, 9pq and 14q, as 
well as amplifications of  chromosomes 1, 3q, 5q, 8q and 12. These profiles 
were consistent with previous reports of associations between deletions of 
9pq and 14q and poor prognosis(Meloni-Ehrig 2002). Other known 
cytogenetic aberrations not previously linked to survival, such as amplification 
of 1q, 3q and deletion of 6q, were highlighted in our study as being of 
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High expression of VEGF-signaling pathway and increased MVD counts are 
associated with good outcomes. We noted during pathway analysis that high 
expression of many genes involved in angiogenesis, hypoxia-response and 
endothelial cell formation optimally predicted longer patient survival. To 
further confirm this, we examined expression of the specific genes involved in 
the canonical VEGF signaling pathway within the 2260 differentially 
expressed transcripts found using significance analysis of microarrays, which 
confirmed this observation (Figure 12, following page). We chose to evaluate 
this hypothesis using IHC to examine microvessel counts. Conventional CD31 
immunostaining yielded a median MVD of 65 vessels / field for 45 tumour 
samples. Using this as a cutoff, univariate analysis demonstrated that 
increased MVD was significantly correlated with prolonged survival (Figure 
14B-D), with R2 of 0.155 (p-value= 0.01).  
 
A pro-angiogenic phenotype is associated with longer survival. We have 
identified externally validated predictors of survival, which correspond to 
distinct molecular subtypes of clear cell RCC. Our results indicate that gene 
expression profiling is a promising adjunct for survival prediction in clear cell 
RCC patients. For clear cell RCC, the uncovered relationship between 
expression of genes associated with hypoxia response, angiogenesis and 
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of cancer biology. This may represent the most interesting biological insight of 
this study. This surprising finding has been hinted at previously in an 
interesting minority of IHC studies (6 of 16 studies) correlating angiogenesis 
and patient survival in clear cell RCC, as contrasted with most other cancers 
where a consensus exists that hypoxia and angiogenesis are directly 
correlated with tumour aggressiveness(Weidner 1998; Weidner 1999). 6 
studies have shown a direct correlation between increasing MVD and 
prolonged survival in RCC(Delahunt et al. 1997; Herbst et al. 1998; Imao et 
al. 2004; Rioux-Leclercq et al. 2001; Sabo et al. 2001; Sandlund et al. 2006), 
5 studies have shown an inverse relationship(Dekel et al. 2002; Joo et al. 
2004; Nativ et al. 1998; Paradis et al. 2000; Yoshino et al. 1995) and 5 
studies have shown no significant correlation(Gelb et al. 1997; Imazano et al. 
1997; MacLennan and Bostwick 1995; Schraml et al. 2002; Slaton et al. 
2001). Our results are consistent with previous reports that RCC vascularity is 
correlated with mRNA expression of HIF-2 (Turner et al. 2002) and 
VEGF(Takahashi et al. 1994), both optimal predictors of longer survival in our 
study. The relationship we observe between tumour aggressiveness and 
angiogenesis suggests a hitherto unanticipated tumour biology underlying 
clear cell RCC. 
 
A biological hypothesis explaining the apparently paradoxical 
relationship between angiogenesis and survival. It is possible that this 
interesting correlation between hypoxia response, angiogenesis and 
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prognosis (Figure 3) may be related to an angioblastic origin of clear cell 
RCC, where different clear cell RCC prognostic groups correspond to various 
clonal subtypes at different endpoints of misdirected differentiation arrest. The 
dominant influence on the expression of genes involved in hypoxic response 
and angiogenesis may thus be similar to the processes driving haematopoetic 
lineage differentiation. There is circumstantial evidence supporting this 
hypothesis. A remarkable morphologic resemblance exists between clear cell 
RCC and haemangioblastoma, both hallmarks of the VHL syndrome. Both 
tumours show immunoreactivity consistent with angioblastic lineage 
arrest(Vortmeyer et al. 2003). Embryonic kidney cells are pluripotent and may 
function as intrinsic, vasculogenic angioblasts that synthesize microvessels 
rather than kidney tissue(Gering et al. 1998; Robert et al. 1996). 
 
Clinical implications of study for therapeutic trials for clear cell 
RCC. There is considerable current interest in clear cell RCC as a model for 
targeted therapy interrupting angiogenesis and hypoxia-response 
pathways(Rini et al. 2009). The results of Phase III trials of multi-targeted 
kinase inhibitors have been announced(Escudier et al. 2007; Motzer et al. 
2007; Sternberg et al. 2010), and various agents aimed at blocking HIF 
mediated pathways are also in development. This molecular prognostic 
predictor is likely to be relevant to Phase II and III trial data interpretation, 
especially where novel anti-angiogenesis or anti-HIF therapies have been 
employed. Our hypothesis of an angioblastic origin of RCC, a conceptual 
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insight paved by expression profiling, opens a new realm of speculation, 
especially with regards to therapy. Further, in view of the unexpected 
correlations between markers of hypoxia, angiogenesis and prognosis in clear 
cell RCC, it will be helpful to determine if good- and poor-prognosis tumours 
exhibit differential responses to anti-angiogenesis and anti-HIF agents. Our 
results also indicate that with appropriate stratification, adjuvant therapy 
should be investigated in individuals with poor-prognosis but apparently 
localized tumours whom are likely to experience disease recurrence following 
primary surgery. 
The prognostic subtypes are clonally distinct. A previous 
microarray study has suggested a metastatic expression signature encoded 
in the majority of cancer cells of a primary tumour(Ramaswamy et al. 2003). 
Given the successful predictions of unsupervised analysis independent of 
clinico-pathologic variables, an interpretation that fits our data more closely is 
that biological aggressiveness in clear cell RCC, rather than metastatic ability 
per se, is established by an early clonal event in tumour progression. Results 
from our test set B, comprising 25 samples of metastatic tumours, clearly 
highlight that metastatic status and biological aggressiveness are 
independent, since several metastatic tumours were also classified as good-
risk tumours. This phenomenon may have been particularly clear in RCC, 
which is well known for a proportion of highly indolent metastatic cancers. As 
such, our results support the existence of at least 2 molecularly distinct clear 
cell RCC clonal subtypes with distinct cytogenetic aberration patterns, each 
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subtype growing and metastasizing at different rates. We confirmed a direct 
prediction of this hypothesis, which was that expression profiles from tumour 
tissue separated from primary tumour by space (metastasis) and time 
(relapse) should be expected to exhibit the same correlation between 
expression signature and survival, as well as similar cytogenetic aberrations. 
These results account for well-known clinical observations where metastatic 
clear cell RCC may be startlingly indolent in a small group of untreated 
patients(Hughes et al. 2000) (Zisman et al. 2001). Inevitably, the question 
arises if this conclusion may be extrapolated to other cancers. An in vitro 
study provides support for this concept by demonstrating an independent 
gene signature for metastasis superimposed upon a poor prognostic gene set 
in a breast cancer cell line(Kang et al. 2003). In establishing that these 
subtypes are preserved over metastasis and relapse, this result emphasizes 
the well-known clinical distinction between tumour aggressiveness and 
metastatic potential per se. 
 
Other prognostic microarray studies of clear cell RCC. The gene 
predictors identified here are externally validated, consistent across array 
platforms and overlap each other. We were able to demonstrate prognostic 
utility for overlapping genes in our predictor and the Stanford dataset of 
Swedish patient(Zhao et al. 2006). No overlap was found between the 
prognostic predictors identified here and a separate microarray study in 
metastatic RCC(Vasselli et al. 2003). This discordance may be a result of the 
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inclusion of non-clear cell RCC histologies in this particular study as well as 
specimen quality concerns. However, concordant prognostic predictions 
among discordant gene predictors are also known(Fan et al. 2006). One 
interesting study (Jones et al. 2005) has sought to define a group of 
‘metastasis-related genes’ in kidney cancer by examining a range of 
histologies of RCC. We have previously speculated that prognostic subtype 
independent of metastasis forms a dominant contribution to variance in renal 
cell carcinoma gene expression(Takahashi et al. 2001). One group has used 
unsupervised analysis to study a small group of tumours, linking expression 
profiles to “tumour aggressiveness” (Kosari et al. 2005), defined by the group 
using a composite index of pathologic scoring, relapse and death.   
 
LIMITATIONS 
Although we were able to demonstrate that our predictor remained 
useful even after adjustment for single variables, including composite 
variables such as the UISS incorporating stage, grade and functional status, 
and that it has remained useful in externally generated datasets, ideally a full 
term model would permit a more measured assessment. Nonetheless, given 
that the generation of this data was through unsupervised analysis, the result 
likely represents a biological reality that clinical parameters are a proxy 
for(Iliopoulos et al. 1996). We were unable to use the Karakiewicz nomogram 
or the Leibovich score due to the absence of data on symptoms and 
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histologic tumour necrosis; it may well have resulted in a different result on a 
corresponding regression model. 
Secondly, the relatively low number of individuals that received 
immunotherapy in each group did not permit multivariate analysis by 
treatment. Nonetheless, given the strength of the predictor in predicting 
survival adjusted by metastatic status, and the documented modest benefits 
of immunotherapy in RCC (Atkins et al. 2004) it is unlikely that our 
conclusions will be modified to a major extent. Thirdly, many of the patients in 
our dataset did not receive targeted therapy, which is the current standard of 
care. It may be argued that it is difficult to do a study on patients on targeted 
therapy using overall survival or CSS as an outcome, as the use of these 
novel agents only became widespread in the last 3 years. There is however 
good data that the clinical prognostic factors that determine outcomes in 
metastatic cancer in the pre-targeted therapy era still drive outcomes in the 
targeted therapy era. 
Thirdly, CGMA as an analytic tool remains fundamentally exploratory, 
focused on virtual karyotyping which requires further definitive validation by 
cytogenetic approaches, particularly for the copy number aberrations 
identified. The implications of CGMA results, particularly in interaction with 
pathway analysis and the generation of expression profile predictors, remain 
uncertain, and more research is needed.  
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CONCLUSION 
In summary, we have identified clinically useful prognostic gene 
predictors for clear cell RCC using gene expression profiling. Increased 
expression of genes classically associated with the VEGF-signaling pathway, 
angiogenesis and the hypoxic response predicted longer patient survival. 
Matching genes of our predictor have prognostic value in a public data set 
that was externally generated. The expression signatures predicted survival in 
metastatic tumour samples resected following patient relapse, leading to a 
speculation that the evolution of subtypes with varying biological 
aggressiveness, propensities for metastasis and cytogenetic aberration 
patterns is determined in early clonal events during tumour progression. A 
hypothesis paved by genomic profiling raises the possibility of an angioblastic 
origin for clear cell RCC. 
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PAPILLARY RCC 
Considering the pathological and clinical issues for papillary RCC discussed 
in Overall Background and Background (Molecular Models), our goal was to 
use gene expression profiling as a promising adjunct for cancer diagnosis and 
prognosis to search for distinct molecular subtypes of papillary RCC that were 
both biologically and clinically relevant. We also sought to identify novel 
immunohistochemical markers for each entity. 
METHODS 
SUBJECTS AND STUDY DESIGN 
A total of 43 primary tumour specimens with a diagnosis of papillary 
RCC after routine pathologic review at 5 medical centers were initially 
collected following nephrectomy. Participating centres were University of 
Chicago, Northwestern University, Spectrum Health Grand Rapids, Johns 
Hopkins University, and University of California Los Angeles. All tumour 
specimens were collected from participating institutions in the United States, 
except one case from Japan. 12 non-neoplastic kidney samples were also 
obtained as controls; these are the same 12 controls for CGMA used for the 
other microarray studies in other subtypes. 
Written informed consent for analysis of clinical samples was obtained 
from all patients, and all institutional review boards of participating institutions 
approved the study. Tumour tissue was flash frozen in liquid nitrogen 
immediately after nephrectomy and stored at –80°C. Portions of the tumours 
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were fixed in buffered formalin. Each sample was confirmed by pathologic 
analysis and anonymized prior to the study. A portion of the tumour sample 
was frozen in liquid nitrogen immediately after surgery and stored at –80˚C. 
Total RNA was isolated from the frozen tissues using Trizol reagent 
(Invitrogen, Carlsbad, CA). This was subsequently purified with a RNeasy kit 
(Qiagen, CA), and quality was assessed on denaturing gel electrophoresis. 
Representative tissue sections of RCC were cut and stained with 
hematoxylin-eosin for confirmation of histological diagnosis and confirmation 
of tumour tissue content (>70%). All samples were examined by a central 
expert uropathologist. Clinicopathologic information was derived by review of 
pathologic, radiologic, and case notes by individual clinicians. Tumours with 
sarcomatoid change were classified as grade 4 tumours. Tumour size was 
defined as the maximum tumour dimension on direct pathological 
measurement. Patient follow-up status was assessed by directly contacting 
patients where possible, or at routine clinical follow-up.  
 
OLIGONUCLEOTIDE ARRAY PROFILING 
For oligonucleotide array gene profiling, we extracted and purified total 
RNA from homogenized samples using Trizol reageant (Invitrogen, CA) 
followed by RNeasy columns (Qiagen, CA) according to manufacturers’ 
recommendations. Oligonucleotide array gene profiling was performed using 
the manufacturer’s recommended protocol (GeneChip Expression Analysis 
Technical Manual, April 2003, Affymetrix, CA). Approximately 5-20 
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micrograms of total RNA was used to prepare antisense biotinylated RNA. A 
subset of cases were spiked with external poly(A) RNA controls. Synthesis of 
single-stranged and double-stranded cDNA was done with the use of T7-
oligo(dT) primer (Affymetrix). In vitro transcription was done using Enzo 
Bioarray Transcript Labeling kit (Enzo, Farmingdale, NY). The biotinylated 
cRNA was subsequently fragmented and 10 micrograms were hybridized to 
each array at 45°C ovr 16 hours. We used the HGU133 Plus 2.0 GeneChip, 
containing 54,675 probe sets, representing approximately 47,000 transcripts 
and variants. Scanning was done in a GeneChip 3000 scanner. Quality 
indices reviewed for all samples included mean percentage present, mean 
background, mean scaling factor and a mean GADPH 3’/5’ ratio (Median 
background was 73, median scaling factor was 3.06, and median GADPH 
3’/5’ ratio was 1.03, indicative of a high overall array and RNA quality).  All 
clinical and microarray data for published data has been uploaded to the 
Gene Expression Omnibus. The gene expression data can be obtained at the 
Gene Expression Omnibus (GSE2748). Because of the sample size (n=34), 
we used supervised analysis, with an internal validation approach. Principal 
component analysis was used to visualize the 34 expression profiles. 
Significance analysis of microarrays (SAM) (Tusher et al. 2001) based on two-
class unpaired analysis, assumption of unequal group variances, and 10,000 
permutations was used to derive a list of genes differentially expressed 
between tumour subclasses and ordered by relative fold change. For 
derivation of a small gene classifier, we used prediction analysis of 
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microarrays (PAM) (Tibshirani et al. 2002), a R implementation of nearest 
shrunken centroids methodology with 10-fold cross-validation over 30 gene 
thresholds and an offset percentage of 30%. Gene predictors corresponding 
to a minimum misclassification error were obtained, with class discriminant 
scores calculated for class 1 and 2 tumours. Two-tailed Student's t test and 
Fisher's exact testing was used to evaluate correlation between variables and 
tumour subclassification. For the purpose of this analysis, tumour grade and 
stage was classified into two categories corresponding to low grade or stage 
(1 and 2) versus high grade and stage (3 and 4).  
 
PATHWAY ANALYSIS 
For pathway analysis in the studies focusing on the molecular aspects 
of RCC, the Ingenuity Pathways database version 3.0 (Ingenuity Systems, 
Mountain View, CA) was used. A list of transcripts was generated using 
significance analysis of microarrays (SAM) based on a 2-class unpaired 
analysis with 1000 permutations. For the study focusing on chromophobe 
RCC and oncocytoma, KEGG pathway(Kanehisa et al. 2010) and gene 
ontology (GO) analysis of enriched gene sets was performed using 
hypergeometric tests available in the GOstats (Falcon and Gentleman 2007) 
package in Bioconductor after having identified unique genes with 
corresponding annotations.  For KEGG pathway analysis, the p-value 
threshold was 0.01.  For GO analysis, conditional testing was performed, and 
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the threshold for p was 0.001.  Molecular function, biologic process, and 
cellular component analyses were performed. 
 
STATISTICAL ANALYSIS 
Statistical analyses were done using R 2.0.1 (Ihaka and Gentleman 1996) 
using packages from the Bioconductor project. The Robust Multichip Average 
algorithm was used to perform preprocessing of the CEL files, including 
background adjustment, quartile normalization, and summarization. Principal 
component analysis was used to visualize the 34 expression profiles. 
Significance analysis of microarrays (SAM) based on two-class unpaired 
analysis, assumption of unequal group variances, and 10,000 permutations 
was used to derive a list of genes differentially expressed between tumour 
subclasses and ordered by relative fold change. We did pathway analysis on 
these genes using Ingenuity Pathway Analysis (Ingenuity Systems, Mountain 
View, CA), and enrichment of canonical pathways was assessed for 
significance by a hypergeometric 
algorithm that did not correct for multiple testing. For derivation of a small 
gene classifier, we used prediction analysis of microarrays (PAM), a R 
implementation of nearest shrunken centroids methodology with 10-fold 
cross-validation over 30 gene thresholds and an offset percentage of 
30%(Tibshirani et al. 2002). Gene predictors corresponding to a minimum 
misclassification error 
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Table 11 : Individual patient demographic data for papillary RCC dataset 








Stage M Stage Grade 
Patient 
status* Survival (Months) 
P 01 46 F Type 2B Class 2 15.2 4 1 3 NA NA 
P 02 59 M Type 1 Class 1 4.5 1 X 1 NA NA 
P 03 68 M Type 1 Class 1 4 1 X 2 NA NA 
P 04 32 M Type 2A Class 1 7 1 X 2 NA NA 
P 05 71 M 
Type 1 and 
2A Class 1 4.7 1 0 2 DOO 30 
P 06 70 M Type 1 Class 1 1.2 3 0 2 NED 26 
P 07 72 F Type 1 Class 1 3 1 0 2 DOO 8 
P 08 73 F Type 1 Class 1 3 1 0 2 NED 25 
P 09 84 F Type 1 Class 1 3.5 1 0 2 NED 27 
P 10 56 F Type 1 Class 1 14 3 0 2 NED 13 
P 11 56 M Type 1 Class 1 3.5 1 0 2 NED 13 
P 12 80 F Type 1 Class 1 2.5 1 0 2 NED 4 
P 13 64 M Type 1 Class 1 5.5 1 0 2 DOD 74 
P 14 44 M Type 1 Class 1 3.5 3 0 2 NED 95 
P 15 76 M 
Type 1 and 
2A Class 1 4.5 1 0 2 NED 58 
P 16 72 M Type 2B Class 2 10 3 0 4 DOD 17 
P 17 55 M Type 1 Class 1 5 3 0 2 NED 30 
P 18 71 F Type 2B Class 2 3 1 0 3 NED 32 
P 19 76 M Type 2B Class 2 5.7 3 0 3 NED 36 
P 20 71 M Type 1 Class 1 2.7 1 0 2 DOO 63 
P 21 80 F Type 2A Class 1 3.5 2 0 2 NED 66 
P 22 53 M 
Type 1 and 
2A Class 1 2.3 1 0 2 NED 61 
P 23 54 M Type 2B Class 2 8 4 0 4 DOD 12 
P 24 50 M Type 2B Class 2 11 3 1 3 DOO 37 
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P 25 44 M Type 2B Class 2 14 4 1 4 AWC 12 
P 26 75 M Type 2A Class 1 9 2 0 2 NA NA 
P 27 74 M 
Type 1 and 
2A Class 1 6 1 0 2 NED 24 
P 28 37 M 
Type 1 and 
2A Class 1 6 1 0 2 DOO 12 
P 29 43 M Type 1 Class 1 5 1 0 2 NA NA 
P 30 63 M Type 2A Class 2 6.9 3 0 2 DOO 34 
P 31 62 M Type 2B Class 2 6.8 4 1 3 DOO 4 
P 32 56 M Type 2B Class 2 6 4 1 3 DOD 16 
P 33 71 F Type 2B Class 2 15 4 1 3 DOD 29 
P 34 49 F Type 2B Class 2 15 4 1 3 DOD 9 
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We visualized the 34 expression profiles by principal component 
analysis. We noted overlap between histologic type 1 and 2 tumours, contrary 
to our expectation of distinct molecular subtypes (Figure 13, page 105). 
Tumours with mixed type 1 and 2 components (n = 5) grouped with type 1 
tumours. PAM with 10-fold cross-validation persistently classified three of four 
low-grade type 2 tumours with type 1 tumours over a wide range of shrinking 
gene thresholds. The only low-grade type 2 tumour that persistently classified 
with the high-grade type 2 tumours was P30 (the only tumour we were unable 
to personally evaluate histologically). These results supported a hypothesis 
that type 2 tumours were molecularly heterogenous. We analyzed the profiles 
based on this morphologic subtyping into two classes (class 1 corresponding 
to type 1, low-grade type 2, and mixed type 1/low-grade type 2 tumours and 
class 2 corresponding to high-grade type 2 tumours) from a molecular 
viewpoint. The first two principal components accounted for 95.7% of all 
variation, allowing for effective clustering. Visualization of the first two 
principal components now showed distinct differentiation between expression 
profiles of class 1 and 2 tumours, consistent with distinct tumour subclasses 
(Fig 15F). Transcripts (n = 796) (available online as Supplemental Data 
http://cancerres.aacrjournals.org/content/vol65/issue13/images/data/5628/DC
1/Supplementary_Table_1.xls) differentially expressed between class 1 and 2 
tumours were identified using SAM at delta of 1.8, with a false discovery rate 
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We were able to identify multiple gene classifiers that effectively differentiated 
class 1 and 2 tumours at 97% accuracy at multiple shrinkage thresholds using 
PAM (between 7 and 3,881 transcripts) using nearest shrunken centroids 
methodology. We report here the seven-transcript predictor that achieved this 
accuracy (Table 12). Only the tumour of P30, initially reported as a type 2 
tumour with grade 2, which we were unable to confirm histologically, 
persistently classified as a class 2 tumour, rather than as a class 1 tumour, 
throughout these multiple shrinkage thresholds. 
 
Table 12 : The 7 transcript predictor discriminating Class 1 and 2 papillary RCC 
Probe ID Gene Description Class.1.score Class.2.score 
232151_at 
MRNA full length insert cDNA clone 
EUROIMAGE 2344436 0.1789 -0.3741
1566766_a_at 
MRNA full length insert cDNA clone 
EUROIMAGE 2344436 0.1419 -0.2967
204304_s_at prominin 1  0.1182 -0.2472
210298_x_at four and a half LIM domains 1 0.0164 -0.0342
201539_s_at four and a half LIM domains 1 0.0159 -0.0332
214505_s_at four and a half LIM domains 1 0.0101 -0.0211
205597_at chromosome 6 open reading frame 29 0.0044 -0.0092
* These class scores are linear discriminant scores for each class as described in the 
reference for significance analysis of microarrays in the text. 
 
 
We list the top 50 transcripts relatively upexpressed in each subclass (Table 
13) (this represents an arbitrary cutoff for presentation, and is not based on a 
p-value threshold) and show a hierarchical clustering of the tumour samples 
based on these 100 transcripts (Figure 14, page 111).
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Table 13 : Top 50 transcripts differentially expressed in Class 1 and 2 papillary RCC 
GENES UPEXPRESSED IN CLASS 1 papillary RCC           
Probe ID Gene Description D(i)* 
Standard 
deviation p-value q-value 
Fold-
Change** 
213456_at sclerostin domain containing 1 -7.2 0.5 0.0 0.0 33.4
201539_s_at four and a half LIM domains 1 -10.9 0.3 0.0 0.0 14.8
204304_s_at prominin 1 -8.0 0.6 0.0 0.0 14.4
210298_x_at four and a half LIM domains 1 -9.9 0.4 0.0 0.0 14.3
214505_s_at four and a half LIM domains 1 -11.3 0.3 0.0 0.0 12.1
210299_s_at four and a half LIM domains 1 -8.1 0.5 0.0 0.0 10.6
209016_s_at keratin 7 -6.9 0.5 0.0 0.0 8.4
205597_at chromosome 6 open reading frame 29 -11.4 0.3 0.0 0.0 8.3
232151_at MRNA full length insert cDNA clone EUROIMAGE 2344436 -9.2 0.4 0.0 0.0 8.0
1566764_at MRNA full length insert cDNA clone EUROIMAGE 2344436 -8.0 0.4 0.0 0.0 7.5
1553809_a_at chromosome 9 open reading frame 71 -6.9 0.3 0.0 0.0 6.5
1566766_a_at MRNA full length insert cDNA clone EUROIMAGE 2344436 -10.0 0.3 0.0 0.0 6.0
224027_at chemokine (C-C motif) ligand 28 -7.2 0.3 0.0 0.0 5.7
1555203_s_at chromosome 6 open reading frame 29 -9.7 0.2 0.0 0.0 5.3
238184_at Transcribed sequences -9.4 0.2 0.0 0.0 4.8
202820_at aryl hydrocarbon receptor -7.2 0.3 0.0 0.0 4.2
202790_at claudin 7 -9.1 0.2 0.0 0.0 4.0
222764_at asparaginase like 1 -8.1 0.2 0.0 0.0 3.9
219127_at hypothetical protein MGC11242 -7.5 0.2 0.0 0.0 3.6
218857_s_at asparaginase like 1 -9.0 0.2 0.0 0.0 3.5
229084_at contactin 4 -6.9 0.2 0.0 0.0 3.4
219614_s_at solute carrier family 6 (neurotransmitter transporter), member 20 -10.1 0.2 0.0 0.0 3.2
210398_x_at fucosyltransferase 6 (alpha (1,3) fucosyltransferase) -8.3 0.2 0.0 0.0 3.1
205405_at Semaphorin 5A -7.3 0.2 0.0 0.0 3.0
1559361_at MRNA full length insert cDNA clone EUROIMAGE 2344436 -8.2 0.2 0.0 0.0 2.8
203365_s_at matrix metalloproteinase 15 (membrane-inserted) -10.0 0.1 0.0 0.0 2.6
229144_at KIAA1026 protein -7.9 0.2 0.0 0.0 2.4
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211110_s_at androgen receptor  -6.9 0.2 0.0 0.0 2.3
223636_at zinc finger, MYND domain containing 12 -7.5 0.1 0.0 0.0 2.2
231022_at Transcribed sequences -7.0 0.2 0.0 0.0 2.2
221665_s_at EPS8-like 1 -8.0 0.1 0.0 0.0 2.1
235937_at Occluding -7.1 0.1 0.0 0.0 2.1
217795_s_at hypothetical protein MGC3222 -7.5 0.1 0.0 0.0 2.1
211621_at androgen receptor -7.3 0.1 0.0 0.0 2.1
210399_x_at fucosyltransferase 6 (alpha (1,3) fucosyltransferase) -7.1 0.1 0.0 0.0 2.0
202005_at 
suppression of tumourigenicity 14 (colon carcinoma, matriptase, 
epithin) -7.1 0.1 0.0 0.0 1.9
243225_at hypothetical protein LOC283481 -7.2 0.1 0.0 0.0 1.9
91826_at EPS8-like 1 -8.2 0.1 0.0 0.0 1.7
218779_x_at EPS8-like 1 -7.5 0.1 0.0 0.0 1.7
205977_s_at EphA1 -9.1 0.1 0.0 0.0 1.6
235293_at CDNA FLJ45593 fis, clone BRTHA3014920 -7.5 0.1 0.0 0.0 1.6
238028_at Similar to hypothetical protein BC006605 (LOC389389), mRNA -7.9 0.1 0.0 0.0 1.6
221655_x_at EPS8-like 1 -7.2 0.1 0.0 0.0 1.5
236058_at hypothetical protein FLJ34633 -8.8 0.1 0.0 0.0 1.5
225778_at RNA binding motif, single stranded interacting protein 2 -6.9 0.1 0.0 0.0 1.5
223724_s_at DKFZp434A0131 protein -6.9 0.1 0.0 0.0 1.5
230111_at 
Transcribed sequence with moderate similarity to protein 
ref:NP_308425.1 -7.4 0.1 0.0 0.0 1.5
226095_s_at hypothetical protein LOC146517 -7.3 0.1 0.0 0.0 1.4
239812_s_at hypothetical protein FLJ12476 -8.1 0.1 0.0 0.0 1.4
238318_at Transcribed sequences -7.1 0.0 0.0 0.0 1.2
 
GENES UPEXPRESSED IN CLASS 2 papillary RCC 
Probe ID Gene Description D(i)* 
Standard 
deviation p-value q-value 
Fold-
Change** 
201292_at topoisomerase (DNA) II alpha 170kDa 6.0 0.4 0.0 0.0 6.5
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202920_at ankyrin 2, neuronal 5.7 0.4 0.0 0.0 5.9
228776_at CDNA FLJ40955 fis, clone UTERU2011199 6.3 0.4 0.0 0.0 4.4
201761_at methylene tetrahydrofolate dehydrogenase (NAD+ dependent) 7.7 0.3 0.0 0.0 4.1
209900_s_at 
solute carrier family 16 (monocarboxylic acid transporters), 
member 1 6.7 0.3 0.0 0.0 3.9
218009_s_at protein regulator of cytokinesis 1  5.6 0.3 0.0 0.0 3.6
202234_s_at 
solute carrier family 16 (monocarboxylic acid transporters), 
member 1 7.1 0.2 0.0 0.0 3.5
209773_s_at ribonucleotide reductase M2 polypeptide 6.2 0.3 0.0 0.0 3.2
210052_s_at TPX2, microtubule-associated protein homolog (Xenopus laevis) 6.5 0.2 0.0 0.0 3.2
218883_s_at KSHV latent nuclear antigen interacting protein 1 5.5 0.3 0.0 0.0 3.1
225655_at ubiquitin-like, containing PHD and RING finger domains, 1 5.6 0.3 0.0 0.0 3.1
218039_at nucleolar and spindle associated protein 1 6.0 0.3 0.0 0.0 3.0
204822_at TTK protein kinase 5.7 0.2 0.0 0.0 2.9
227607_at 
associated molecule with the SH3 domain of STAM (AMSH) like 
protein 5.8 0.3 0.0 0.0 2.8
201664_at SMC4 structural maintenance of chromosomes 4-like 1 (yeast) 7.8 0.2 0.0 0.0 2.7
201663_s_at SMC4 structural maintenance of chromosomes 4-like 1 (yeast) 5.7 0.2 0.0 0.0 2.5
212110_at solute carrier family 39 (zinc transporter), member 14 5.6 0.2 0.0 0.0 2.5
203554_x_at pituitary tumour-transforming 1 6.3 0.2 0.0 0.0 2.5
202338_at thymidine kinase 1, soluble 5.9 0.2 0.0 0.0 2.3
1555758_a_at cyclin-dependent kinase inhibitor 3  5.8 0.2 0.0 0.0 2.3
202954_at ubiquitin-conjugating enzyme E2 6.2 0.2 0.0 0.0 2.2
1554408_a_at thymidine kinase 1, soluble 6.1 0.2 0.0 0.0 2.2
227606_s_at 
associated molecule with the SH3 domain of STAM (AMSH) like 
protein 5.6 0.2 0.0 0.0 2.1
203764_at discs, large homolog 7 (Drosophila) 5.9 0.2 0.0 0.0 2.1
221923_s_at nucleophosmin (nucleolar phosphoprotein B23, numatrin) 5.7 0.2 0.0 0.0 2.0
212295_s_at solute carrier family 7, member 1 5.4 0.2 0.0 0.0 2.0
204092_s_at serine/threonine kinase 6 5.6 0.2 0.0 0.0 2.0
202705_at cyclin B2 5.7 0.2 0.0 0.0 1.9
213188_s_at MYC induced nuclear antigen 5.8 0.2 0.0 0.0 1.9
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228245_s_at ovostatin 2 6.0 0.2 0.0 0.0 1.9
207828_s_at centromere protein F, 350/400ka (mitosin) 5.6 0.2 0.0 0.0 1.9
205345_at BRCA1 associated RING domain 1 5.6 0.2 0.0 0.0 1.9
203669_s_at diacylglycerol O-acyltransferase homolog 1 (mouse) 5.8 0.1 0.0 0.0 1.8
213689_x_at ribosomal protein L5 5.8 0.1 0.0 0.0 1.7
203562_at fasciculation and elongation protein zeta 1 (zygin I) 5.6 0.1 0.0 0.0 1.7
214096_s_at serine hydroxymethyltransferase 2 (mitochondrial) 5.4 0.1 0.0 0.0 1.7
205651_x_at Rap guanine nucleotide exchange factor (GEF) 4 5.4 0.1 0.0 0.0 1.7
213947_s_at nucleoporin 210 5.7 0.1 0.0 0.0 1.7
230165_at shugoshin-like 2 (S. pombe) 5.4 0.1 0.0 0.0 1.6
218950_at 
ARF-GAP, RHO-GAP, ankyrin repeat and plekstrin homology 
domains-containing protein 3 6.5 0.1 0.0 0.0 1.6
203022_at ribonuclease H2, large subunit 6.4 0.1 0.0 0.0 1.5
203719_at excision repair cross-complementing rodent repair deficiency 6.3 0.1 0.0 0.0 1.5
218115_at ASF1 anti-silencing function 1 homolog B (S. cerevisiae) 5.4 0.1 0.0 0.0 1.5
210023_s_at likely ortholog of mouse nervous system polycomb 1 6.1 0.1 0.0 0.0 1.4
221591_s_at hypothetical protein FLJ10156 5.6 0.1 0.0 0.0 1.4
204126_s_at CDC45 cell division cycle 45-like (S. cerevisiae) 6.7 0.1 0.0 0.0 1.3
214426_x_at chromatin assembly factor 1, subunit A (p150) 5.9 0.1 0.0 0.0 1.3
212313_at hypothetical protein MGC29816 5.9 0.1 0.0 0.0 1.3
221779_at molecule interacting with Rab13 5.8 0.1 0.0 0.0 1.3
239680_at hypothetical protein FLJ12973 6.0 0.1 0.0 0.0 1.3
  
 
 * D(i) is a modified t-statistic calculated by SAM. 
 ** Fold-change is shown in terms of a relationship between the tumour with higher expression relative to the tumour 
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Survival analysis  showed that this refined morphologic and molecular 
classification system showed a survival prediction that showed a statistically 
insignificant edge over the previous morphology-based classification 
approach (Nagelkerke's R2 = 0.505 and P = 0.001 versus R2 = 0.389 and P = 
0.005). Class 2 tumours were larger in tumour dimension (P = 0.003), of 
higher grade (P < 0.001), of higher stage (P < 0.001), and were more likely to 
exhibit distant metastases at initial surgery (P < 0.001) than class 1 tumours. 
Indeed, all tumours metastatic at initial surgery were class 2 tumours (n = 7). 
No significant difference in age (P = 0.37) or gender (P = 0.70) was found 
between the two classes.  
Chromosomal aberrations inferred by CGMA. Distinct cytogenetic 
profiles for each tumour were generated using high-resolution CGMA (Figure 
15, following page) Full-length gains in chromosomes 7, 12, 16, 17, and 20 
was found both in class 1 and 2 tumours, consistent with the previously 
reported trisomies observed by using conventional cytogenetic analysis 
characteristic of papillary RCC. However, in comparison with class 1 tumours, 
class 2 tumours exhibited more frequent gains at 1q, 2, and 8q and losses at 
3p and 6q and showed fewer gains of chromosome 3, 7, and 16. More 
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Table 14 : Immunohistochemical results for Class 1 and Class 2 papillary RCC 
  






Profiled tumours Type 1 0 0 10 10 0 0 
  Type 2A 0 0 1 1 0 0 
  Mixed Type 1 and 2A0 1 2 3 0 0 
  Type 2B 4 1 0 0 1 4 
Independent tumours Type 1 0 1 4 5 0 0 
  Type 2A 1 0 1 0 2 0 
  Mixed Type 1 and 2A0 0 0 0 0 0 
  Type 2B 6 2 0 0 0 8 
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Morphologic classification. The morphologic classification of papillary 
RCC into type 1 and 2 tumours has been supported by several histologic studies, 
although there is relatively limited molecular evidence to substantiate this 
subtyping. There remains controversy over the recent proposed morphologic 
classification system of papillary RCC, preventing its widespread application. For 
example, there is no agreement whether a tumour with eosinophilic cytoplasm 
but low nuclear grade should be classified as type 1 or 2. In the initial proposal 
outlining this morphologic subtyping. 63% of type 2 tumours were assessed as 
being of low Fuhrman nuclear grade despite pleomorphic nuclei being defined as 
a characteristic of type 2 tumours (Delahunt and Eble 1997). More recently, Allory 
et al. classified only 1 of 13 (8%) as low-grade type 2 tumours using a modified 
criteria (Allory et al. 2003). The high frequency of tumours with coexisting type 1 
and 2 components poses difficulties for such a binary classification, the 
prevalence of such mixed tumours having been reported as high as 28%. Allory 
et al. chose to classify these tumours with mixed (type 1 and 2) features as type 1 
tumours, an approach in line with our molecular classification.  
Molecular classification. Our results provide only partial support for the 
proposed histologic subtyping of papillary RCC into type 1 and 2 tumours. Type 2 
tumours are molecularly heterogenous, with a subset of type 2 (low-grade) 
tumours and mixed type 1 and 2 tumours demonstrating molecular profiles more 
consistent with type 1 tumours. These type 2 tumours were all low-grade tumours 
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and showed excellent clinical outcomes, in contrast with the poor outcomes 
recorded in high-grade type 2 tumours. Type 2 papillary RCC is composed of at 
least two genetically distinct subtypes: one subtype (type 2A) resembles type 1 in 
terms of indolent tumour behavior, excellent survival, low tumour grade, similar 
expression profiles, immunoreactivity, and inferred cytogenetic profiles; the other 
subtype (type 2B) is an highly metastatic, aggressive cancer that is molecularly 
distinct from type 1 or 2A tumours. Our findings support a view that nuclear grade 
is the key correlate for a molecular classification with both biological and clinical 
relevance, with features such as cell size or cytoplasmic eosinophilia being more 
peripheral. Additional distinctive histopathologic features for these subclasses 
may be defined with a larger series. In this report, the molecular classification 
showed a statistically insignificant edge in prognostication over the previously 
proposed histologic classification. However, the molecular approach with 
correlation to nuclear grade may be more relevant, as it also accurately classifies 
mixed type 1 and 2 tumours, which are not well accounted for in the histologic 
classification. This refined classification of papillary RCC based on both 
morphologic features and molecular studies may be more relevant and is likely to 
benefit diagnosis, prognostication, clinical follow-up, and experimental selection 
of therapeutic targets.  
We successfully generated an internally validated seven-transcript 
predictor, which was able to classify class 1 and 2 tumours with 97% accuracy, 
the only misclassification arising from a tumour (P30) that we were unable to 
personally evaluate. Consistent with our microarray classification, this tumour 
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from P30 behaved in an aggressive fashion, the patient relapsing 2 years after 
surgery. The patient died of a non-cancer-related cause 10 months after relapse. 
External validation in a second population is required for assessment of true 
generalizability of these gene predictors, but these results are very encouraging.  
Inferred cytogenetic profiles. Aneuploidy is well established as a key 
driver of global gene expression, and regional DNA copy number correlates well 
with regional expression in cancer, which we have also shown in RCC 
classification. Papillary RCC typically shows frequent trisomies of chromosomes 
7, 12, 16, 17, and 20 (Amin et al. 1997) (Kovacs et al. 1991) (Kattar et al. 1997). 
For papillary RCC subclassification, our results are strictly not directly 
comparable with recent cytogenetic studies that have classified their results by 
the type 1 and 2 classification (Jiang et al. 1998) (Gunawan et al. 2003). As 
expected, our inferred cytogenetic profiles were consistent with previous studies 
correlating cytogenetic findings with tumour grade; Lager et al. identifying less 
frequent trisomy of 7 in high-grade tumours (Lager et al. 1995) and Renshaw and 
Corless reporting that trisomy of 3 was found in a defined subset of low-grade 
papillary RCC tumours (Renshaw and Corless 1995). In addition to these 
findings, in demonstrating that loss of 9q occurred more commonly in class 2 
tumours, our results support a report that loss of heterozygosity at 9q is 
associated with reduced survival.  
Immunohistochemical findings. To validate the gene predictor and to 


































































er work is r
egulation. D
in class 1 t
 been repo
nd Corless
ype 1 and 2
ith finding







































d of Topo I





 and Eble 1
lly upexpre











e of the ce
e role of m
 of the FH










 RCC and 
 RCC as th
sed genes
mplicated i














 20% of 
HC marker
e 2 




















mutated in a group of families with type 2 papillary RCC (Tomlinson et al. 2002), 
was not observed (data not shown).  
The implication of dysregulation of the G2-M checkpoint regulation in class 
2 tumours is particularly interesting from a therapeutic point of view. We took a 
particular interest in DNA TopII, which we additionally established as a diagnostic 
marker for class 2 tumours. As there is no effective medical therapy for advanced 
papillary RCC and this enzyme is associated with the more aggressive papillary 
RCC subclass, TopII inhibitors are distinct possibilities for a therapeutic trial of 
papillary RCC. G2 arrest occurs in response to these agents (Clifford et al. 2003) 
and may therefore be particularly appropriate. Although several kidney cancer 
trials have reported disappointing results for TopII inhibitors (Escudier et al. 2002; 
Law et al. 1994), these trials have predominantly recruited patients with clear cell 
RCC, a genetically distinct disease. In further support of this suggestion, a 
previous study reports that this gene is the most overexpressed gene in pediatric 
Wilms' tumour, for which current therapeutic regimens consisting primarily of 
TopII inhibitors are very effective(Takahashi et al. 2002).  
Clonal origin versus progression. It has been hypothesized previously 
based on cytogenetic findings that type 1 tumours progress to type 2 
tumours(Gunawan et al. 2003). Prudent evaluation of our results in the context of 
this hypothesis is required. Although microarrays of gross tumour tissue show a 
global expression signature presumably reflective of early clonal events 
(Ramaswamy et al. 2003), it is plausible that a competitive growth advantage 
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may accrue to the transformation of a single cell into a class 2 within a class 1 
tumour, resulting in its expansion at the expense of other class 1 tumour cells. 
Nonetheless, the additional presence of a distinct group of mixed tumours with 
coexisting type 1 and 2A histology and presenting with molecular profiles 
resembling other type 1 tumours strongly suggests that type 1 and 2A tumours 
are clonally more closely related to each other than to type 2B tumours. We did 
not note the presence of low-grade components in any of our type 2B tumours. 
Given the divergent survival outcomes following nephrectomy between class 1 
(type 1, type 2A, and mixed type 1/2A tumours) and class 2 tumours, we do not 
favor the idea of progression between class 1 and 2 tumours. 
In terms of specific limitations to this study, the relatively small sample size 
requires subsequent validation in a larger study. Additionally, future pathway 
analysis is likely to benefit from novel methods to control for multiple testing in 
pathway analysis.  Certainly the findings of dysregulation of G1-S checkpoint 
genes in class 1 papillary RCC and dysregulation of G2-M checkpoint genes in 
class 2 papillary RCC should be deemed to be exploratory, requiring validation in 
a second study.  
CONCLUSION 
In conclusion, using gene expression profiling supported by 
immunohistochemical and morphologic studies, we have identified two distinct 
classes of papillary RCC that differ strikingly in their clinical behavior and have 
dysregulation of genes controlling different parts of the cell cycle. This finding 
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represents a biologically and clinically relevant refinement to previously proposed 
morphologic criteria for subclassification of papillary RCC. We summarize our 
findings that may be practically evaluated in the clinical setting laboratory as 
follows: class 2 (type 2B) papillary RCC may be distinguished from class 1 (type 
1, mixed type 1 and 2A, and type 2A tumours) by the following characteristics: 
larger gross tumour size, higher nuclear grade (3-4), decreased CK7 staining and 
increased Top II alpha staining, higher rate 
of metastases at surgery, and poorer patient survival. Morphologic findings of 
less specificity include larger cell size and eosinophilic cytoplasm in class 2 
tumours. Our findings may benefit further efforts to elucidate the molecular basis 
of development and progression of papillary RCC and will be helpful in stratifying 
patients for additional interventions. 
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CHROMOPHOBE RCC AND ONCOCYTOMA 
Considering the pathological and clinical issues for chromophobe RCC and 
oncocytoma discussed in Overall Background and Background (Molecular 
Models), our goal was to perform a comprehensive characterization of both 
enetities by integrating gene expression and high resolution single-nucleotide 
polymorphism (SNP) profiling for the identification of a useful and valid molecular 
predictor. We also sought to identify novel immunohistochemical markers for 
each entity. Further to identifying novel cytogenetic abnormalities underlying the 
two entities, we chose to investigate further the specific genes and pathways that 
may be responsible for dysregulation of gene expression.  
METHODS 
SUBJECTS AND STUDY DESIGN 
A total of 30 frozen primary kidney tumours (15 chromophobe RCC and 15 
oncocytomas) were obtained from the French Kidney Tumours Consortium, 
University of Chicago, Northwestern University, and Spectrum Health Hospital 
(Grand Rapids, MI). 12 non-neoplastic kidney samples were also obtained as 
controls for regional expression bias analysis. 
Written informed consent for analysis of clinical samples was obtained 
from all patients, and all IRB boards of participating institutions approved the 
study. Tumour tissue was flash frozen in liquid nitrogen immediately after 
nephrectomy and stored at –80°C. Portions of the tumours were fixed in buffered 
formalin. Each sample was confirmed by pathologic analysis and anonymized 
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prior to the study. A portion of the tumour sample was frozen in liquid nitrogen 
immediately after surgery and stored at –80˚C. Total RNA was isolated from the 
frozen tissues using Trizol reagent (Invitrogen, Carlsbad, CA). This was 
subsequently purified with a RNeasy kit (Qiagen, CA), and quality was assessed 
on denaturing gel electrophoresis. Representative tissue sections of RCC were 
cut and stained with hematoxylin-eosin for confirmation of histological diagnosis 
and confirmation of tumour tissue content (>70%). All samples were examined by 
a central expert uropathologist (X.Y.). Clinicopathologic information was derived 
by review of pathologic, radiologic, and case notes by individual clinicians. 
Tumours with sarcomatoid change were classified as grade 4 tumours. Tumour 
size was defined as the maximum tumour dimension on direct pathological 
measurement. Patient follow-up status was assessed by directly contacting 
patients where possible, or at routine clinical follow-up. 12 non-neoplastic kidney 
samples from unrelated patients were also obtained as controls for regional 
expression bias analysis; these are the same 12 controls for regional expression 
bias used for the other microarray studies in other subtypes in this thesis. 
OLIGONUCLEOTIDE ARRAY PROFILING 
For oligonucleotide array gene profiling, we extracted and purified total RNA from 
homogenized samples using Trizol reageant (Invitrogen, CA) followed by RNeasy 
columns (Qiagen, CA) according to manufacturers’ recommendations. 
Oligonucleotide array gene profiling was performed using the manufacturer’s 
recommended protocol (GeneChip Expression Analysis Technical Manual, April 
2003, Affymetrix, CA). Approximately 5-20 micrograms of total RNA was used to 
 128
prepare antisense biotinylated RNA. A subset of cases were spiked with external 
poly(A) RNA controls. Synthesis of single-stranged and double-stranded cDNA 
was done with the use of T7-oligo(dT) primer (Affymetrix). In vitro transcription 
was done using Enzo Bioarray Transcript Labeling kit (Enzo, Farmingdale, NY). 
The biotinylated cRNA was subsequently fragmented and 10 micrograms were 
hybridized to each array at 45°C ovr 16 hours. We used the HGU133 Plus 2.0 
GeneChip, containing 54,675 probe sets, representing approximately 47,000 
transcripts and variants. Scanning was done in a GeneChip 3000 scanner. 
Quality indices reviewed for all samples included mean percentage present, 
mean background, mean scaling factor and a mean GADPH 3’/5’ ratio).  All 
clinical and microarray data for published data has been uploaded to the Gene 
Expression Omnibus. The gene expression data can be obtained at the Gene 
Expression Omnibus (GSE19982). For external validation in a dataset with 
oncocytoma and chromophobe data, an external GEO data-set of gene 
expression profiles of oncocytomas and chRCC from Cornell University was 
obtained for validation (GSE12090) (Rohan et al. 2006). Statistical analyses were 
performed in the statistical environment R 2.6.0, utilizing packages from the 
Bioconductor project. Data preprocessing was performed using the RMA method 
as implemented in the affy package and using updated probe set mappings such 
that a single probe set describes each gene (Dai et al. 2005) (Gentleman et al. 
2004). Chromosomal abnormalities were predicted using the comparative 
genomic microarray analysis (CGMA) method as implemented in the reb 
package (Furge et al. 2005). Briefly, for each measured gene, the gene 
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expression value was normalized such that the average gene expression value in 
the nondiseased samples was subtracted from the tumour-derived gene 
expression value. A Welsh's t-test was applied to the relative gene expression 
values that mapped to each chromosome arm. For the smoothing curve, the 
normalized expression values derived from genes mapping to chromosome 19 
were replaced by a summary score that comprised a running two-sided t-test 
statistic using window sizes of 61, 245, and 611 (representing 5%, 20%, and 50% 
of the length of the chromosome). The results of the three smoothing curves 
were averaged. For purposes of hierarchical analysis using complete linkage 
analysis, probe set filtering for coefficient of variation (0.05, with at least 2 
samples showing log2 value expression of 8) was performed.  Significance 
analysis of microarrays (SAM) on unfiltered data based on two-class unpaired 
analysis, assumption of unequal group variances and 10,000 permutations was 
used to derive a list of probe sets differentially expressed between tumour 
subclasses, and ordered by relative fold-change. A maximum false discovery rate 
threshold was defined as 0.05.  
PATHWAY ANALYSIS 
KEGG pathway(Kanehisa et al. 2010) and gene ontology (GO) analysis of 
enriched gene sets was performed using hypergeometric tests available in the 
GOstats (Falcon and Gentleman 2007) package in Bioconductor after having 
identified unique genes with corresponding annotations.  For KEGG pathway 
analysis, the p-value threshold was 0.01.  For GO analysis, conditional testing 
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was performed, and the threshold for p was 0.001.  Molecular function, biologic 
process, and cellular component analyses were performed. 
SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS 
An independent set of samples were obtained from the Cooperative 
Human Tissue Network (CHTN) for high throughput single-nucleotide 
polymorphism (SNP) array analysis (chromophobe RCC n=6 and oncocytoma 
n=8). A Jetquick DNA extraction kit (Genomed, Lohne, Germany) was used to 
isolate DNA based on manufacturer’s protocol. The SNP assay was performed 
according to the manufacturer’s instructions using the Affymetrix GeneChip 
mapping 100K array (Affymetrix, Santa Clara, CA). Image quantification was 
performed using a GeneChip Scanner 3000, and the resulting data was 
processed using GCOS 1.4 (Affymetrix). Allele calls were generated using 
Affymetrix GeneChip Genotyping analysis (GTYPE v.4) with a confidence 
threshold set at 0.25. Raw copy numbers in log-transformed format (non-paired 
reference and test samples) were exported from the CNAG version 2.0 
(Affymetrix) software using normal references downloaded from Affymetrix 
(http://www.affymetrix.com;ccnt_reference_data). The NCBI human genome 
reference build 36 was used for analysis. DNA copy number changes were 
visualized using data smoothing in which raw copy number values were replaced 
by a summary score that comprised a running 1-sided t test statistic with window 
size set to 31, where each SNP probe along with 15 5’ SNP and 15 3’ SNPs were 
included in the window. DNA copy number data can be obtained at the Gene 
Expression Omnibus (GSE8271) 
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IMMUNOHISTOCHEMISTRY 
IHC staining was performed on an independent set of chromophobe RCC 
(n=11) and oncocytomas (n=7).  Aquaporin 6 and synaptogrin 3 were selected 
from the PAM (Table 1).  Parafibromin (218578_at) (2-fold mean expression 
difference) and cytokeratin 7 (209016_s_at) were selected from the SAM 
analysis of the gene expression profiles for validation. Candidate marker choice 
was determined by factors including fold-change, specificity, biological and 
clinical interest. CK7, a previously recognized marker, was selected here for 
testing to ascertain the additional benefit of routine pathologic practice in the 
samples. Briefly, following blocking and antigen retrieval, 4-micron sections on 
coated slides were incubated with the following antibodies: a mouse anti-
cytokeratin 7 monoclonal antibody (DakoCytomation, Carpinteria, CA, 1:50, 
cytoplasmic staining), a polyclonal rabbit anti-human aquaporin 6 (AQP6, Alpha 
Diagnostic International, San Antonio, TX, 1:100, overnight at 4C, membranous 
staining), polyclonal goat anti-synaptogyrin 3 N-18 and C-18 antibodies 
(SYNGR3, Santa Cruz Biotechnology, Santa Cruz, CA, cytoplasmic and 
membranous staining), an mouse monoclonal anti-parafibromin antibody (1:250, 
1 hour at room temperature, nuclear staining) (Tan et al. 2004a), a rabbit 
monoclonal anti-HER2 antibody (Neomarker RM 9103-S clone SP3, 1:200, 
membranous staining), a phospho-AKT (Ser473) antibody (Cell Signaling 
Technology, 1:30, cytoplasmic and nuclear staining). For the latter two 
antibodies, 22 chromophobe RCC and 8 oncocytoma specimens were available. 
For p-AKT, staining in the stromal and tumour cell compartments was separately 
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assessed.  Subsequent reactions were performed with biotin-free HRP enzyme 
labeled polymer of EnVision Plus detection system (DakoCytomation). All slides 
were examined by a pathologist in a blinded fashion.  
 
FLUORESCENT IN SITU HYBRIZATION AND WHOLE CHROMOSOME 
PAINTING 
For fluorescent in-situ hybridization and whole chromosome painting, 
bacterial artificial chromosomes (BACs) RP11-157B13 (19p12), RP11-1137G4 
(19p13.3), RP11-15A1 (19q13.31) were obtained from the Children's Hospital 
Oakland Research Institute and BAC CTC-429C10 (19q13.41) was purchased 
from Invitrogen (Invitrogen Corporation, Carlsbad, CA). These clones were 
labeled with either SpectrumGreen or SpectrumOrange (Abbott Molecular Inc, 
Des Plaines, IL) by nick translation and applied to tissue touch preps of 
oncocytoma samples as described, with the exception that slides were 
counterstained with VECTASHIELD (Vector Laboratories, Inc. Burlingame, CA) 
anti-fade 4′,6-diamidino-2-phenylindole (DAPI). Telomere-specific DNA probes, 
the chr 1,5,19 alpha satellite probe, and the arm-specific paints were purchased 
from Q-BIOgene (MP Biomedicals, Solon, OH). FISH was performed using these 
probes according to the manufacturer's supplied protocol. As the alpha satellite 
probe cross-hybridizes to chromosome 1 and chromosome 5, in all studies 
chromosome 19 was co-labeled with a probe that maps distal to the centromere, 
RP11-157B13 (19p12). In addition, analysis of the centromeric probe on the 
metaphase spreads of control cells revealed that hybridization to chromosome 1 
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resulted in a significantly brighter signal (data not shown). These hybridization 
characteristics allowed the discrimination between chr 1 and 5 cross-
hybridization. For image quantification, three separate photomicrographs 
containing five, six, and three cells, respectively, in which the 19q31.31 FISH 
signals were in the same image plane were obtained. Photomicrographs were 
processed using the rtiff package for the R environment. The fluorescent FISH 
signals were automatically segmented from background using the method of 
Ridler and Calvard, individual spots were identified using the connected 
component algorithm, and the number of pixels per feature were calculated. 
Twelve doublet FISH signals and eight singlet FISH signals were compared. 
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A gene predictor comprising 14 probe sets was identified (Table 15), 
which yielded an overall accuracy of 93% in the internal data-set (28/30) (Table 
16, next page).  The same predictor successfully classified 17 of 18 samples in 
the external dataset from Cornell University, corresponding to an overall 
accuracy of 94% (Table 15).  5,210 probe sets were found to be differentially 
expressed between the two entities as identified using SAM at a delta of 1.4, with 
a false discovery rate of 0.03 corresponding to an estimated 222 probe sets. 
2,564 number of probe sets were relatively overexpressed in chromophobe RCC, 
and 2,646 transcripts relatively underexpressed in chromophobe RCC. 
 
Table 15 : Predictor derived by nearest shrunken centroid methodology for sample 
classification of chromophobe RCC and oncocytoma 
 
Affymetrix 















aquaporin 6 -0.1218 0.1218 0.22 
 
205691_at synaptogyrin 3 0.1108 -0.1108 3.75 
 
230110_at mucolipin 2 -0.0731 0.0731 0.15 
 
52940_at single immunoglobulin and toll-
interleukin receptor (TIR) 
domain 
0.0577 -0.0577 3.28 
 
217879_at cell division cycle 27 homolog 
(S. cerevisiae) 
 
-0.0403 0.0403 0. 
222574_s_
at 
DEAH (Asp-Glu-Ala-His) box 
polypeptide 40 





* A class discriminant score derived from nearest shrunken centroids 
methodology. 




Table 16 : Predictor performance in sample classification in distinguishing chromophobe 
RCC and oncocytoma in internal and external datasets 
  Gene predictor (14 probe sets) 




Internal Data-Set chromophobe RCC 13/15 (87%) 2/15 (13%) 




RCC 8/9 (89%) 1/9 (11%) 
(Cornell) Oncocytoma 0/9 (0%) 9/9 (100%) 
 
 
218921_at single immunoglobulin and toll-
interleukin receptor (TIR) 
domain 
0.0205 -0.0205 3.16 
 
230644_at leucine rich repeat and 
fibronectin type III  domain 
containing 5 
0.0172 -0.0172 4.90 
 
223087_at enoyl Coenzyme A hydratase 
domain containing 1 





(ubiquinone) Fe-S protein 1 
-0.0093 0.0093 0.46 
 
202502_at acyl-Coenzyme A 
dehydrogenase 




Immunohistochemical findings The IHC profiling is summarized in 
Table 17 and Figure 19 (next page), results of which were consistent with the 
microarray quantitation. The immunoreactivity of chromophobe RCC to 
cytokeratin 7 was higher than that of oncocytomas and normal kidney.  For 
parafibromin, clear differential staining was noted, with predominantly nuclear 
expression in oncocytomas, and absent expression in chromophobe RCC.  For 
synaptogyrin-3, both N-18 and C-18 antibodies yielded a similar signal, but the N-
18 antibody yielded a crisper result though the maximal signal was distinctly 
weaker compared to AQP6, for which crisp membranous staining was noted in 
oncocytoma, but not in chromophobe RCC. For p-AKT, there was an apparent 
but non-significant higher immunoreactivity in chromophobe RCC than 
oncocytoma, particularly in the stromal cells relative to the tumour cells. For 
extracellular HER2, all samples were unreactive.  
 
Table 17 : Results of IHC staining showing sample discrimination between chromophobe 
RCC and oncocytoma. 
 
 chromophobe RCC Oncocytoma  
Protein Positive Negative Positive Negative P-value 
AQP6 3/11 (28%) 8/11 (72%) 6/7 (86%) 1/7 (14%) 0.05 
Parafibromin 1/11 (9%) 10/11 (91%) 5/7 (71%) 2/7 (29%) 0.01 
CK7 8/11 (72%) 3/11 (27%) 1/7 (14%) 6/7 (86%) 0.05 
SYNGR3 9/11 (82%) 2/11 (18%) 0/7 (0%) 7/7 (100%) 0.002 
p-AKT 




(tumour) 13/22 (59%) 8/22 (41%) 4/8 (50%) 4/8 (50%) 0.68 
Extracellular 
HER2 0/22 (0%) 
22/22 
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Pathway Analysis. Pathway and GO analysis was performed on the SAM 
analysis, demonstrating an enrichment of genes involved in metabolic pathways 
in oncocytomas relative to chromophobe RCC (Table 18, next page).  These 
metabolic pathways include oxidative phosphorylation, amino acid metabolism, 
and fatty acid metabolism.  Conversely, high expression of genes involved in cell 
adhesion, immune receptor signaling as well as proliferative pathways such as c-
erbB2 (Her-2/neu) and mammalian target of rapamycin (mTOR) signaling are 
detected in chromophobe RCC.  Further gene ontology analyses (not presented) 
performed supported these results highlighting that mitochondrial genes were 
highly overrepresented among genes relatively overexpressed in oncocytomas, 
whereas tight junction genes were similarly overrepresented among genes 
overexpressed in chromophobe RCC. 
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Table 18 : Molecular pathways discriminating chromophobe RCC and oncocytoma 
Pathways relatively upregulated in oncocytoma 
KEGGID   Pvalue  OddsRatio  ExpCount  Count  Size  Term 
280 0 6.206 4 17 44 Valine, leucine and isoleucine degradation 
640 0 6.349 3 13 33 Propanoate metabolism 
190 0 3.093 11 27 114 Oxidative phosphorylation 
970 0 4.488 4 12 38 Aminoacyl-tRNA biosynthesis 
20 0.001 4.833 3 9 27 Citrate cycle (TCA cycle) 
330 0.001 4.032 3 10 34 Arginine and proline metabolism 
4120 0.003 3.13 4 11 45 Ubiquitin mediated proteolysis  
 
Pathways relatively upregulated in chromophobe RCC 
KEGGID   Pvalue  OddsRatio  ExpCount  Count  Size  Term 
4660 0 3.263 9 23 93 T cell receptor signaling pathway 
4662 0 3.945 6 18 63 B cell receptor signaling pathway 
4514 0 2.505 12 26 129 Cell adhesion molecules (CAMs) 
4670 0 2.676 10 23 108 Leukocyte transendothelial migration 
5220 0 3.05 7 18 76 Chronic myeloid leukemia 
5212 0 2.977 7 17 73 Pancreatic cancer 
4520 0.001 2.823 7 17 76 Adherens junction 
5130 0.001 3.335 5 13 51 Pathogenic Escherichia coli infection - EHEC 
5131 0.001 3.335 5 13 51 Pathogenic Escherichia coli infection - EPEC 
4530 0.001 2.277 11 22 117 Tight junction 
4664 0.001 2.65 7 16 75 Fc epsilon RI signaling pathway 
4620 0.003 2.268 10 19 101 Toll-like receptor signaling pathway 
4012 0.003 2.372 8 17 87 ErbB signaling pathway 
564 0.003 2.621 6 14 66 Glycerophospholipid metabolism 
4150 0.004 2.964 4 11 47 mTOR signaling pathway 
5120 0.004 2.523 6 14 68 Epithelial cell signaling in Helicobacter pylori infection
4210 0.005 2.293 8 16 84 Apoptosis 
4070 0.006 2.317 7 15 78 Phosphatidylinositol signaling system 
4540 0.007 2.124 9 17 95 Gap junction 
4912 0.009 2.07 9 17 97 GnRH signaling pathway 
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We report in particular that our high throughput methods demonstrate that 
there is a common gene alteration to both tumours (loss of chromosome 1p), 
which may represent an early event common in the histogenesis of both tumours. 
Otherwise, consistent with previous cytogenetic studies, the renal oncocytoma 
cells were largely devoid of transcriptional abnormalities that would reflect a DNA 
amplification or deletion. In contrast, losses of chromosomes  2, 6, 10, and 17 are 
frequently found in chromophobe RCC. In our chromophobe RCC samples, these 
well-established chromosomal losses were strongly reflected in the gene 
expression profiling data. In addition, a transcriptional abnormality involving 
genes mapping to chromosome 19 was frequently identified in both the renal 
oncocytomas and the chromophobe RCCs. In renal oncocytomas, the 
transcriptional abnormality primarily involved the q arm of chromosome 19, while 
in chromophobe RCC the abnormality involved the entire chromosome (Figure 
22, next page). For each gene on chromosome 19, the average log2-transformed 
expression ratio comparing oncocytoma or chromophobe RCC to non-diseased 
kidney was plotted relative to genomic location (Figure 22, next page). A 
smoothing curve was fit to the log2-transformed data to highlight regions that 
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Semi-quantitative image analysis was used to examine the characteristics 
of the large FISH singlet (Figure 23, preceding page) This analysis demonstrated 
that the size of the singlet FISH signal was on average 1.5-fold larger than the 
size of two well-separated 19q FISH signals (P = 0.02). This large signal was 
observed using multiple probes directed against the q arm of the chromosome, 
including centromeric and telomeric probes (Figure 23, preceding page). The 
large FISH singlet had striking similarities to the FISH signals observed in studies 
of somatically paired chromosomes. Somatic pairing refers to the close 
association of homologous chromosomes and is typically associated with 
chromosomes in meiotic prophase. However, somatic pairing has also been 
observed in interphase in normal human cells and some tumour cells. The 
presence of a large FISH singlet reflects the overlapping FISH signals generated 
from two chromosomal regions in very close proximity. The lack of evidence for a 
DNA copy number change coupled with the presence of large FISH singlets and 
proximal doublets using multiple locus-specific probes, suggested that chr 19q 
was somatically paired. To confirm that the q arms of chr 19 were somatically 
paired in the renal oncocytoma cells, the p and q arms of chr 19 were visualized 
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ChRCC and oncocytoma are morphologic and genetically related entities, 
and distinction between these two tumours is important because of their different 
biological behaviors.  However, these entities can be difficult to distinguish 
morphologically.  We report the derivation of a novel and useful gene predictor 
validated both on an internal and an independent external data-set, implying its 
generalizability.  Our results suggest that it is possible to classify accurately 
histopathologically challenging tumours. The degree of accuracy achieved at 
93% is reasonable for a genetic classifier. However integration into clinical 
practice requires a comprehensive evaluation of these classifiers within a clinical 
setting, comparing clinical outcomes in routine pathologic evaluation relative to 
that derived from novel classifiers. This may be most practically if not most ideally 
done in a retrospective fashion on paraffin-embedded tissue in a large multi-
institutional collaboration, which we are currently pursuing. This issue may 
become progressively more important with the increase in incidentally detected 
small tumours on radiologic surveillance, where the dilemma between 
observation or intervention is commonly posed. 
Novel cytogenetic alterations both common and discriminating. 
Integrating RNA and DNA genomic data allows us to verify genomic alterations in 
tumour samples and distinguish the genomic signatures of different tumour 
subtypes.  Frequent losses of chromosome 1, 2, 6, 10, 13, 17, and 21 and gains 
in chromosome 4, 7, 11, 12, 14q and 18q were observed in chromophobe RCC, 
consistent with previously reported data(Bugert and Kovacs 1996). For renal 
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oncocytoma, we show a high prevalence of chromosome 1p loss.  Both 
chromophobe RCC and oncocytoma share this chromosomal alteration, 
consistent with a speculation that this may represent an early event in neoplastic 
transformation of a common progenitor cell.  
Chromosome 1p loss represents a common cytogenetic alteration in both 
chromophobe RCC and renal oncocytoma identified by high-throughput SNP 
studies.  This may suggest that this is an early event in the histogenesis of both 
tumours, before additional cellular events lead to malignancy in lesions that 
progress to chromophobe RCC, similar to chromosome 3p loss in clear cell RCC, 
which is thought to be an early event in carcinogenesis.  Loss of chromosome 1p 
has been identified recently in renal oncocytoma(Picken et al. 2008), but this has 
not been previously shown to be a common cytogenetic alteration common to 
both entities, which is the key insight.  Our delineation of the nature of 
chromosome 1p loss in renal oncocytoma provides the opportunity to identify 
novel tumour suppressor genes in future studies, and in establishing a possible 
carcinogenesis progression sequence.  
Pathway identification in oncocytoma and chromophobe RCC. There 
has been a recent advent of targeted therapies for a wide variety of cancers.  
Given the relative rarity of chromophobe RCC, there is no current standard of 
care and it is unlikely that any specific clinical trial is feasible or will be initiated.  
Here, we report two clinically relevant pathways—the c-erbB2/HER2 pathway 
and the mTOR signaling pathway—are dysregulated in chromophobe RCC on 
exploratory pathway analysis of mRNA expression, but our evaluation of 
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cxtracellular HER2 and phospho-AKT IHC expression has not provided direct 
support for this mRNA finding. On a clinical trial level, in a subgroup analysis of a 
Phase III trial of temsirolimus, an mTOR inhibitor, in poor-prognosis RCC of all 
subtypes, patients of non-clear cell histology benefited as much as patients with 
clear cell histology, if not more(Hudes et al. 2007).  Our findings do not permit a 
single definitive conclusion about the nature of pathway activation in these two 
entities. Currently, mTOR inhibitors remain a clinical standard of care for poor-
risk metastatic non-clear cell RCC. HER2 expression has been evaluated in 
chromophobe RCC and oncocytoma, with distinct patterns of peptide expression 
varying according to epitope(Seliger et al. 2000). Interestingly, this study showed 
that strong intracellular HER2 expression (as defined by a 3+ expression) was 
strongly expressed in chromophobe RCC (9/19) but not in oncocytoma (1/11), 
whereas neither chromophobe RCC nor oncocytoma showed strong extracellular 
HER2 expression. Further evaluation of this is warranted, in conjunction with 
relevant fluorescent in-situ hybridization studies.  
It has been previously reported that oxidative phosphorylation and energy 
pathway genes are overexpressed in chromophobe RCC and renal oncocytoma 
relative to the other subtypes of RCC(Schuetz et al. 2005). We are able to clarify 
this issue, demonstrating that even between these two entities, there are major 
differences in quantitative expression of the same pathways discriminating the 
two entities.  Consistent with these results, it has been recently reported that 
oncocytomas exhibit mitochondrial DNA mutations with clonal expansion and 
complex I deficiencies(Gasparre et al. 2008; Mayr et al. 2008). Oncocytoma 
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contains a large number of mitochondria, and the overexpression of these genes 
involved in cellular metabolism may reflect the relative quantitative excess of the 
mitochondria. A similar profound modification in energy metabolism genes has 
been observed in thyroid oncocytomas(Baris et al. 2004), with high activity of the 
aerobic respiratory pathway. It may be speculated that potential inhibition of 
autophagy in the chromophobe RCC may correspond to this difference as well. 
Rohan et al have previously reported in a smaller data-set that gene expression 
profiling is able to discriminate oncocytomas and chromophobe RCC(Rohan et 
al. 2006), and has reported that vesicular transport and cell junction proteins are 
relatively upregulated in chromophobe RCC.  
Novel biomarker identification discriminating chromophobe RCC and 
oncocytoma. In the process of validating our high-throughput expression 
studies, we report three novel markers discriminating between chromophobe 
RCC and oncocytoma: parafibromin, aquaporin 6, and synaptogyrin 3.  
Parafibromin, the protein product of the HRPT2 tumour suppressor gene, has 
been reported to be downregulated in a variety of tumours(Selvarajan et al. 2008; 
Tan et al. 2004a), and a role has been assigned to it in the Wnt signaling 
pathway(Mosimann et al. 2006). While the mechanism of parafibromin 
downregulation in parathyroid carcinoma appears to be mediated through gene 
mutation, this does not seem to be the mechanism in chromophobe RCC, as we 
have not identified any HRPT2 mutations after analyzing DNA samples from 5 
chromophobe RCC tumours (data not shown).  Similarly, other investigators have 
reported allelic imbalances in the HRPT2 gene in oncocytoma and chromophobe 
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RCC, but no mutations(Zhao et al. 2007).  Aquaporin 6 is an intracellular vesicle 
water channel protein reported to be expressed in the intercalated cells of the 
collecting duct(Yasui et al. 1999), which is hypothesized to be the originating cell 
for oncocytoma and chromophobe RCC.  Little is known about synaptogyrin-3, a 
tyrosine-phosphorylated protein that is expressed in synaptic vesicles(Belizaire et 
al. 2004).  The reasons underlying the reduced expression of aquaporin 6 and 
increased expression of synaptogyrin-3 in chromophobe RCC, relative to 
oncocytoma are uncertain. 
Based on our transcriptional and genomic DNA studies, we reveal somatic 
pairing of chr 19q as a recurrent cytogenetic abnormality in renal oncocytoma 
that results in dramatic changes in transcription within the paired region. Somatic 
pairing refers to the close association of homologous chromosomes and is 
typically associated with chromosomes in meiotic prophase. However, somatic 
pairing has also been observed in interphase in normal human cells and some 
tumour cells (Atkin and Jackson 1996; Brown et al. 1994; Lewis et al. 1993; 
Zhang et al. 1997). The functional consequence of chromosome joining is 
formally unknown but it is may disrupt chromatin structure causing the 
juxtaposition of cis and trans regulatory regions that modulate the transcription of 
a large set of genes. The changes in gene expression that accompanied the 
somatic pairing suggested that deregulation of a gene, or multiple genes, 
associated with tumour development mapped within the paired chr 19q region. 
The identification of EGLN2 as a significantly deregulated gene that maps within 
the paired chromosome 19q region directly implicates defects in the oxygen-
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sensing network to the pathobiology of renal oncocytoma. These results suggest 
that in addition to numerical and structural chromosomal abnormalities, somatic 
pairing should be considered as a chromosomal event that associates with 
tumourigenesis. 
Hypoxia-response dysregulation in chromophobe RCC and 
oncocytoma. A proper oxygen-sensing response is vital to the maintenance of 
normal cellular functions. Deregulation of HIF, the principal driver of the adaptive 
response to hypoxia, is associated with the pathogenesis of several diseases, 
including cancer. While the hypoxic tumour microenvironment - by the virtue of 
the ubiquitous oxygen-sensing pathway - results in modulation of HIF activity, 
loss-of-function mutations in a growing list of tumour suppressor genes also can 
affect HIF function. Mutations in PTEN, PML, TSC, and VHL have been identified 
in tumour cells that result in the deregulation of HIF via multiple distinct 
mechanisms involving Akt/PI3K, mTOR and the ubiquitin pathway. Emerging 
evidence now implicates cancer-causing mutations that directly impinge on 
EGLNs. For example, mutations in succinate dehydrogenase (SDH) result in the 
cytosolic accumulation of succinate, which inhibits EGLNs, leading to the 
stabilization and activation of HIF-1α. Inactivating germline mutations in EGLN1 
have been identified to cause erythrocytosis (Percy et al. 2006; Takeda et al. 
2008) and deregulation of EGLN3 has been linked to the development of 
pheochromocytoma, a neuroendocrine tumour of the adrenal glands(Lee et al. 
2005). 
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The disruption of HIF activity has been associated with kidney cancer 
related to VHL disease, sporadic clear cell RCC, and hereditary papillary 
RCC(Isaacs et al. 2005; Pollard et al. 2005; Tomlinson et al. 2002). 
CONCLUSION 
In conclusion, we have comprehensively characterized the molecular 
proiles of chromophone RCC and oncocytoma using high throughput expression 
and SNP profling. We have consequently derived discriminating expression 
signatures, pathways, cytogenetic profiles and protein markers that are of 
biologic, clinical and therapeutic interest. The present study reveals deregulation 
of the oxygen-sensing response in renal oncocytoma, as well as chromophobe 
RCCs (which display DNA amplification mediated up-regulation of EGLN2) and 
thereby supporting the dysfunction of HIF pathway as a common and perhaps 




Given that multiple studies in this thesis rely on the use of high throughput 
technology such as gene expression profiling and single nucleotide 
polymorphism analysis, it is important to evaluate novel issues and 
considerations of this technology in common. Here I present several limitations 
common to all the studies in the Molecular Models section of this study, from both 
a classical as well as from a pathological viewpoint. 
 
STUDY DESIGN  
I will broadly focus on the issues of study design and validity in this 
discussion of the epidemiologic issues generated within the work on the 
molecular models, rather than focus on individual limitations arising within each 
individual paper. Describing these high-level overall limitations here also aids in 
reducing unnecessary duplication in the various sections. These issues are 
primarily related to the high-throughput technologies employed, before continuing 
with discussion of the individual issues in each paper. In essence, standard 
epidemiologic issues remain as relevant, if not more so, in this era of high 
throughput technology. 
VALIDITY 
In terms of internal validity, many conclusions for each study was 
generated from an initial sample set of frozen tissue samples from a wide range 
of centres that were made available to the Van Andel Research Institute for 
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research. As such, the issue of selection bias needs to be comprehensively 
discussed. Frozen tissue samples are relatively inaccessible. Legacy samples 
are often archived in tissue banks overseen by pathologists, and often with no 
clinical data available. Hence, while modern tissue banks have been addressing 
these issues, these are necessary and practical limitations to working with 
retrospective tissue samples of the past (and thus with long follow-up). While we 
were careful to define the time period for samples, it is necessary to accept that 
there may be some bias introduced in the assessment of the importance of these 
genetic markers by a retrospective design. Hence, for all studies, it was critical to 
introduce a degree of external validation by an independent sample set. For the 
study focusing on clear cell RCC, in addition to our internal sample set of primary 
clear cell RCC samples, our results were separately validated in terms of (i) an 
independent Swedish cDNA microarray data-set, across platforms (Larkin et al. 
2005) (ii) immunohistochemistry on an independent paraffin-embedded tissue 
set. This was validated in terms of immunohistochemistry on an independent 
paraffin-embedded tissue set. For the chromophobe RCC study, this was 
validated in terms of (i) a separate oligonucleotide array data-set of 
corresponding samples that is openly accessible and (ii) an independent set of 
tissue samples. With more sample sets becoming available in the foreseeable 
future (albeit largely selected hospital-based samples), external validation studies 




In terms of analytic validity, our study uses primarily high throughput 
techniques to elicit genome-level biomarkers against conventional survival based 
outcomes. Analytic validity is a major concern of high throughput technology – in 
particular, issues of bias introduced at the various steps of experiment design, 
sample processing, measurement, quantification, scanning  and data 
analysis(Zervakis et al. 2009). Further, on a meta-analytic level, the use of the 
same samples in different studies also may result in bias. Our studies use a 
common commercial platform – the Affymetrix U133Plus 2.0 microarray platform, 
with its own internal controls for sample quality (e.g. GADPH 3’-5’ ratios). Multiple 
replicates, both biologic and technical, are required for reducing the noise 
generated by analysis of high-dimensional data such as the microarray data we 
generate here (Larkin et al. 2005). It should be noted that multiple probesets for 
each gene may exist on this platform, and that only a subset of these probesets 
may be identified in a predictor. It is unclear that summarizing the multiple 
probeset data into a single gene expression value is superior to interpreting 
individual probeset expression values. 
It is well recognized that tumour tissue is heterogenous(Liu 2007). The 
studies here are based on microarrays of bulk tissue, inclusive of both tumour 
and stroma. Laser microdissection studies have shown that these two 
compartments differ in terms of gene expression profiles(Gregg et al. 2010). 
Nonetheless, it is important to note that the epidemiologic outcomes measured 
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here are primarily survival based, and thus, our primary interest is essentially 
external validation of a clinical based predictor. Indeed, the use of bulk tissue 
samples for microarray analysis may even yield insights, best seen in our work 
on clear cell RCC, where we suggest that the molecular determinants of 
prognosis may occur early in clonal development of a cancer cell, rather than 
arise later in individual subclones. 
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OVERALL CONCLUSIONS AND FUTURE RESEARCH 
In this work, we evaluate multiple clinical models for use in predicting 
outcomes in RCC, and determine that molecular studies may improve or 
complement these results, improving both clinical predictions and yielding useful 
biological insights. We describe the contributions in these specific areas as 
follows. 
For clinical models, we are able to determine that in terms of evaluating all 
the relevant clinical models, the Karakiewicz nomogram is superior to all other 
tested models in terms of predicting survival outcomes in localized RCC. In 
comparing models in current use in ongoing pharmaceutical trials, the Leibovich 
clinical trial criteria is superior to the UISS clinical trial criteria in terms of 
prediction of relapse free survival, but is equivalent to the UISS trial criteria in the 
prediction of CSS and OS. Exploratory analysis that we have performed is able to 
determine a potentially useful survival cutoff (a 5 year estimated cancer-specific 
survival of 0.9) for the Karakiewicz nomogram for dichotomization. This cut-off 
should be considered for use in future adjuvant trial design.  
We have surveyed multiple pathological subtypes of RCC for our 
molecular model analysis. For clear cell RCC, we have identified clinically useful 
prognostic gene predictors for clear cell RCC using gene expression profiling. 
Increased expression of genes classically associated with the VEGF-signaling 
pathway, angiogenesis and the hypoxic response predicted longer patient 
survival. 
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For papillary RCC, we have identified two distinct molecular classes of 
papillary RCC that differ strikingly in their clinical behavior and have dysregulation 
of genes controlling different parts of the cell cycle. This finding represents a 
biologically and clinically relevant refinement to previously proposed morphologic 
criteria for subclassification of papillary RCC. 
For chromophobe RCC, we have comprehensively characterized the 
molecular profiles of chromophobe RCC and oncocytoma using high throughput 
expression and SNP profiling.  We have consequently derived discriminating 
expression signatures, pathways, cytogenetic profiles and protein markers that 
are of biologic, clinical and therapeutic interest. Additionally, we show that while 
chromophobe RCC cells contain an extra copy of chromosome 19, the renal 
oncocytoma cells contain a rarely reported chromosomal abnormality. Both of 
these chromosomal abnormalities result in transcriptional disruptions of EGLN2, 
a gene that is located on chromosome 19. Defects in oxygen sensing are found 
in other types of kidney tumours, and the identification of EGLN2 directly 
implicates defects in the oxygen-sensing network in these neoplasias as well.  
Overall, this thesis thus provides insights into both classic and molecular 
epidemiology, representing a useful evaluation of existing statistical prognostic 
models for RCC, with immediate practical value for clinical practice, 
epidemiologic research and trial design. The use of molecular profiling for all 
major subtypes of RCC in this thesis has yielded novel subtypes for clear cell 
RCC and papillary RCC, with attending biologic, clinical and epidemiologic 
implications. The molecular predictors differentiating chromophobe RCC and 
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oncocytoma have provided useful insights as to the underlying biology, as well as 
provided opportunities for practical differentiation between these two highly 
related entities in the pathology laboratory.  
FUTURE RESEARCH 
This thesis lays out the molecular epidemiology of RCC as discerned 
through both a clinical and epidemiologic lens, predominantly with gene 
expression profiling techniques. These results clearly show the heterogeneity of 
RCC in terms of gene expression and survival outcomes. As such, it would be 
important to utilize the insights afforded by this subtyping in future epidemiologic 
studies of RCC, thereby clarifying the associated factors predisposing to, and 
influencing outcomes of RCC such as prognosis and drug response.  
From a biological viewpoint, evaluation of the molecular basis of these 
subtypes is crucial. Toward this goal, cancer genetics and epigenetics may be 
viewed as fundamental to investigating the dysregulated gene expression 
identified here. In particular, with improvements in next-generation sequencing 
technology and the identification of new somatic alterations such as mutations of 
PBRM1, such approaches will likely provide more information on the basis of the 
molecular epidemiology observed here. With better characterization of each 
sample, it is inevitable that more complex analyses will be possible. 
From a clinical viewpoint, these novel subtypes are useful for utilization in 
the context of clinical research. It is likely that different RCC subtypes even within 
the same pathological subtype may yield different outcomes when treated with 
different targeted therapies, particularly if the underlying genetics of these 
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subtypes differ. Hence, the use of our clinical and molecular predictors would be 
very relevant in the context of international drug trials. It is already recognized 
that even within clear cell RCC, indolent tumours respond better to anti-
angiogenic therapy and more aggressive tumours respond better to mTOR 
inhibitors. The extension of clinical trials as currently designed to accommodate 
novel insights of molecular epidemiology can improve study recruitment and 
outcomes.  
In particular, this thesis focuses primarily on the epidemiology of RCC, in 
terms of diagnosis and prognosis. With the approval of many novel targeted 
therapies for cancer in the last five years, the use of these agents for the 
treatment of RCC has become of major interest. Hence, the issue of how biology 
affects therapeutic response is a key future research area, and this work provides 
a clear biological foundation for this challenge.  
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